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Abstract 
 
 Chronic exposure of humans or rodents to high calorie diets leads to 
hypertriglyceridemia and ectopic lipid deposition throughout the body, resulting in 
metabolic disease. Cellular lipids are stored in organelles termed lipid droplets 
(LDs) that are regulated by tissue-specific LD proteins. These proteins are critical 
for lipid homeostasis, as humans with LD protein mutations manifest metabolic 
dysfunction. Identification of novel components of the LD machinery could shed 
light on human disease mechanisms and suggest potential therapeutics for Type 
2 Diabetes. 
 Microarray analyses pinpointed the largely unstudied Hypoxia-Inducible 
Gene 2 (Hig2) as a gene that was highly expressed in obese human adipocytes. 
Imaging studies demonstrated that Hig2 localized to LDs in mouse hepatocytes 
and the human SGBS adipocyte cell line.  Thus, this work examined the role of 
Hig2 as a LD protein in liver and adipose tissue. 
 Hig2 deficiency reduced triglyceride deposition in hepatocytes; conversely, 
ectopic Hig2 expression promoted lipid deposition. Furthermore, liver-specific 
Hig2-deficient mice displayed improved glucose tolerance and reduced liver 
triglyceride content. Hig2 deficiency increased lipolysis and -oxidation, 
accounting for the reduced triglyceride accumulation.  
 Similarly, adipocyte-specific Hig2-deficient mice displayed improved 
glucose tolerance, reduced adipose tissue weight and brown adipose tissue that 
vii 
 
 
was largely cleared of lipids. These improvements were abrogated when the 
animals were placed in thermoneutral housing and brown adipocyte-specific 
Hig2-deficient mice also displayed improved glucose tolerance, suggesting that 
active brown fat largely mediates the metabolic phenotype of Hig2 deletion. 
Thus, this work demonstrates that Hig2 localizes to LDs in liver and adipose 
tissue and promotes glucose intolerance. 
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Part1: Lipid Deposition in health and disease 
 Lipids act as a critical energy reservoir. Their formation, storage and 
breakdown are tightly controlled by signaling pathways that will be detailed 
below. Two organs that function as master regulators of lipid synthesis and 
storage are the liver and adipose tissue. In healthy animals, both liver and 
adipose tissue synthesize lipids to be stored largely in white adipose tissue. 
Thus, the first part of chapter 1 will focus on the roles of liver and adipose tissue 
in lipid deposition.     
Liver 
Structure 
 The liver is organized into lobes; hepatocytes, marked by the lineage 
marker albumin, make up 80% of the cell population (1). Most hepatocytes in 
mature liver are multinucleated and thus, tetraploid, and function in nutrient 
processing (2). The remainder of the liver cell population consists of resident 
immune cells, endothelial cells, and a variety of stem cells. Kupffer cells (KCs), 
the resident macrophages of the liver, are the most numerous tissue-resident 
macrophage in the body, and have distinct subpopulations (3). These cells often 
present the first line of defense for blood-borne infections and KC-depleted mice 
display 100% lethality when exposed to certain infections (4,5). Hepatic stellate 
cells (HSCs) store lipids and vitamin A in a healthy liver, but become highly 
proliferative and fibrinogenic in a chronically inflamed liver (3). The liver has a 
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remarkable capacity for regeneration and the role of pluripotent stem cells and 
multipotent oval cells in this process is still debated, as hepatocytes appear to 
divide and regenerate the majority of liver after partial hepatectomy (6).   
Function 
 The liver is a master regulator of immune surveillance, detoxification, 
serum protein synthesis, and whole body metabolism. The hepatic immune 
system differs from that of other organs because it must maintain a level of 
immunosuppression due to its exposure to LPS, a bacterially-derived 
polysaccharide, but it must be capable of being fully activated when exposed to 
blood-borne infections (3). The liver removes and breaks down circulating toxic 
compounds such as ammonia, bilirubin, and ethanol (7). The liver also functions 
in secretion of plasma proteins such as albumin and clotting factors (8). As 
discussed in detail below, the liver acts as a master regulator of whole body 
metabolism (Figure 1.1). During times of caloric excess, the liver synthesizes and 
exports or stores lipids and during fasting or starvation, it synthesizes and 
exports glucose. The liver also plays a key role in the synthesis and recycling of 
glycogen and bile acids (9,10).  
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Figure 1.1 Lipid metabolism in liver 
 
 
FIGURE 1.1 Lipid metabolism in liver. The liver is a master regulator of lipid 
metabolism. Fatty acids that are esterified into triglycerides (TG) in the liver can 
come from multiple sources, such as adipose tissue lipolysis, the diet, or 
synthesis directly from glucose via de novo lipogenesis. Triglycerides can be 
packaged and exported in very low-density (VLDL) lipoprotein particles or can be 
broken down to fatty acids and oxidized by the mitochondria. TG; triglyceride, 
VLDL; very low-density lipoprotein. 
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De Novo Lipogenesis 
 De novo (DNL) lipogenesis is the postprandial synthesis of lipids from 
protein or carbohydrate metabolites. Both liver and adipose tissue synthesize 
lipids via the de novo lipogenic pathway and the contribution of each tissue is 
often species-specific (11). Experiments suggest that in humans and rodents, 
DNL predominantly occurs in liver, while in ruminants, the adipose tissue 
synthesizes most of the lipids (11). DNL builds FAs from acetyl units, which 
usually come from glucose or acetate, and acetyl-CoA. Glucose enters the cell 
via the glucose transporter Glut2 (12). Glucose is converted to pyruvate by 
glycolysis and pyruvate is converted to citrate within the TCA cycle. ATP citrate 
lyase (ACLY) converts citrate and CoA to acetyl-CoA. Acetyl-CoA carboxylase 
(ACC) is the rate-limiting enzyme for FA synthesis and converts acetyl-CoA to 
malonyl-CoA. Fatty acid synthase (FAS) synthesizes the FA palmitate from 
malonyl-CoA and acetyl-CoA. Other FAs are synthesized by elongation and/or 
desaturation of palmitate.  Two FA molecules are esterified to a molecule of 
glycerol phosphate by the enzyme Glycerol-P Acyl-Transferase (GPAT) to form 
triglyceride (TG) (11). DNL is highly coupled to nutrient availability and the 
transcription factors that regulate the expression of most lipogenic enzymes are 
upstream stimulatory factors (USFs), Sterol regulatory-element binding protein 1 
(SREBP1), Carbohydrate regulatory-element binding protein (ChREBP), and 
Liver x receptor LXR (13). Transcription of lipogenic enzymes, such as FAS, is 
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increased by insulin and decreased by fasting, coupling them with nutrient 
availability (11,14). TGs synthesized de novo can either be stored in hepatic lipid 
droplets (LDs) or exported into circulation as very low density lipoprotein (vLDL) 
particles.   
Lipid uptake and secretion 
 The liver functions both in the secretion of lipid-containing lipoprotein 
particles and the uptake of lipoprotein remnants. The synthesis and secretion of 
vLDL occur in hepatocytes and are well-characterized. TGs and cholesterol are 
synthesized in the smooth ER and transferred to lipoprotein particles containing 
apolipoprotein B-100 (ApoB-100) by microsomal triglyceride transfer protein 
(Mttp). Lipid and ApoB-100-containing vesicles diffuse to the Golgi where they 
are glycosylated and bud off. The vesicles fuse with the hepatocyte sinusoidal 
membrane and are released into circulation (11).  
 Conversely, dietary FAs from chylomicrons, which are circulating 
cholesterol, phospholipid, and TG-containing lipoprotein particles from the 
intestine, are taken up by muscle and adipose tissue, leaving chylomicron 
remnants (CR) (15). Hepatocytes take up CR via the hepatic low density 
lipoprotein receptor (LDLR) or LDLR-related protein 1 (LRP1) (16-19). 
Delipidated vLDL remnants are similarly recycled (15). 
 Hepatic Glucose Production 
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 During prolonged fasting, the liver must synthesize and export glucose to 
maintain blood glucose concentrations. Initially, glucose is formed from 
glycogenolysis, the breakdown of stored hepatic glycogen (20). Upon depletion 
of glycogen stores, glucose is synthesized from glycerol, lactate, or amino acids 
(AAs) by gluconeogenesis. These substrates, which are often derived from 
muscle or adipose tissue, enter the cytoplasm via transporters, and are 
converted to pyruvate. Pyruvate is converted to oxaloacetate by pyruvate 
carboxylase (PC), then converted to phosphoenolpyruvate (PEP) by 
phosphoenolpyruvate carboxykinase (PEPCK). In a series of steps, PEP is 
converted to fructose 6-phosphate, then glucose 6-phosphate and finally to 
glucose by glucose-6-phosphatase (Glu-6-Pase), which can then be released 
into the bloodstream (21).   
 Gluconeogenic enzyme activity is increased by both glucagon and 
glucocorticoids and decreased by insulin, coupling gluconeogenesis with fed-
fasting state (21-23). The transcription factors that promote gluconeogenic 
enzyme expression are Forkhead box O1 (FOXO1), peroxisome proliferator-
activated receptor gamma coactivator 1 alpha (PGC1 cAMP-responsive 
element binding protein (CREB)/ CREB-regulated transcription coactivator 2 
(Crtc2), CCAAT enhancer-binding proteins (C/EBPs), and hepatocyte nuclear 
factors (HNFs). During fasting, these factors translocate to the nucleus and 
activate gluconeogenic genes (24-27). Although it has been established that 
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hormones control hepatic glucose production, the precise mechanisms whereby 
this happens are unclear. One hypothesis, which couples adipose tissue lipolysis 
to hepatic glucose production suggests that insulin suppresses adipose tissue 
lipolysis, which reduces the availability of the substrate acetyl-CoA for hepatic 
gluconeogenesis, thereby reducing gluconeogenic enzyme levels (particularly 
PC) and hepatic gluconeogenesis (28).  
Glycogen Synthesis 
 Glycogen consists of large branched polymers of glucose stored in 
cytoplasmic granules in hepatocytes and it functions as a ready glucose supply in 
liver. During fasting, glycogen is the first source of glucose released by the liver 
to maintain euglycemia (10). Glycogen stores can also be found in skeletal 
muscle. Glycogen is converted first to glucose 1-phospate then glucose 6-
phosphate by phosphoglucomutase and finally to glucose by Glu-6-Pase, which 
can then be released into the bloodstream (10). Glycogen synthesis and 
breakdown are hormonally regulated, coupling glucose availability to fed-fasting 
state (20). 
Adipose Tissue 
 The adipose tissue is a critical energy reservoir and an endocrine organ. 
What was once considered an inert fat storage organ has evolved into a key 
regulator of whole body metabolism. Adipose tissue is actively involved in lipid 
and glucose uptake, de novo lipid synthesis, lipolysis, and the secretion of 
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adipose-specific cytokines, termed adipokines. The necessity of adipose tissue is 
confirmed by the metabolic disease and related comorbidities of patients that 
lack functional adipose tissue. The role of adipose tissue in health and disease 
will be discussed in detail below. 
Structure  
 The adipose tissue is a heterogeneous organ comprised of fat cells, also 
known as adipocytes, which can number up to two-thirds of the cell population, 
and a range of other cells including stem cells, fibroblasts, endothelial cells, 
blood cells, and neuronal cells (29,30). These cells, when digested and 
fractionated from the adipocytes, are collectively called the stromal vascular 
fraction or the SVF (31). Experiments have established that multipotent cells 
capable of forming fat pads in vitro and in vivo reside in the SVF (32-34). 
Although the exact developmental origin of these adipose tissue stem cells is still 
unclear, numerous hypotheses exist. One hypothesis suggests that these stem 
cells arise from a vascular niche as a subset of perivascular mural cells (33), 
while another suggests that endothelial cells and/or hematopoietic cells can 
change cell fate to give rise to adipocyte stem cells (35-38). Adipose tissue 
resides in many different depots in mammals and these depots are formed and 
remodeled throughout the life of the organism. Three classifications of adipose 
tissue, which have differing structures and functions will be described below.  
White Adipose Tissue  
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 White adipose tissue (WAT) is the primary site of energy storage in 
animals. White adipocytes store energy in the form of neutral lipids in a large, 
unilocular organelle termed a lipid droplet (LD), which will be described in detail 
later in the chapter (39). The prominent WAT depots in humans are the visceral, 
consisting of the omental, mesenteric, and retroperitoneal depots and the 
subcutaneous, consisting of the abdominal and gluteofemoral depots (40). The 
prominent WAT depots in mice are the visceral, consisting of the perigonadal, the 
retroperitoneal, the perirenal, and the mesenteric depots and the subcutaneous, 
consisting of the inguinal, interscapular, subscapular, axillary and cervical depots 
(39,41). Experimental evidence suggests that the subcutaneous and visceral 
depots are phenotypically distinct by a number of measures. The subcutaneous 
depot is associated with insulin sensitivity, is resistant to lipolysis, and expands 
primarily via hypertrophy during obesity (42-44). In mice, transplanting 
subcutaneous adipose tissue but not visceral adipose tissue into a visceral depot 
improves metabolic health, thus, this depot is considered a beneficial adipose 
depot (45). The visceral fat depot, perhaps due to its proximity to other organs 
and the liver portal vein, is prone to inflammation during metabolic disease, is 
highly lipolytic and, expands by both hypertrophy and hyperplasia during obesity 
(42-44,46).  
Brown Adipose Tissue 
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 Brown adipose tissue (BAT) is characterized by multilocular adipocytes, a 
high vascular density, and large numbers of mitochondria, which contribute to its 
brown color (39). A primary function of BAT is to generate heat by nonshivering 
thermogenesis, which occurs by uncoupling of oxidative metabolism (47). BAT 
forms during embryonic development in mammals and has its own specific gene 
expression program, which will be discussed below (48). While adult mice have 
BAT depots, until recently it was thought that BAT was only present in neonatal 
humans to generate necessary heat, but it was determined through analysis of 
fluorodeoxyglucose positron emission tomography (FDG-PET) scans that 
humans retain some portion of BAT through adulthood (49-51). The primary BAT 
depots in humans are located in the supraclavicular and subscapular regions, 
while mice have interscapular, subscapular, cervical, periaortic, and perirenal 
BAT depots (40,47,52). Retrospective analysis of FDG-PET scans demonstrate 
that BAT is associated with insulin sensitivity in humans and inversely associated 
with BMI, age, and fasting glucose levels (53,54). 
Beige/Brite Adipose Tissue 
 Although WAT and BAT comprise the majority of adipose tissue in 
humans and rodents, beige (55) or brite (brown in white) (56) adipose tissue is 
being thoroughly investigated due to its inducible therapeutic potential. 
Interestingly, certain depots of adipose tissue have demonstrated plasticity 
depending on ambient temperature (57). For instance, cold temperatures 
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increase catecholamine levels thereby activating BAT to maintain body 
temperature. Conversely, it is less active at warm temperatures (39). Additionally, 
in colder temperatures, catecholamines activate certain populations of cells in 
WAT, particularly those in the subcutaneous depots. These beige/brite cells 
acquire more mitochondria and multilocular LDs, much like brown adipocytes 
(58). As these adipocytes possess characteristics of both white and brown 
adipocytes, they are termed beige/brite adipocytes. Although the source of these 
cells (conversion from mature white cells (59) vs de novo differentiation of 
precursors (42)) is controversial, the act of certain WAT cells expressing beige 
adipocytes markers is often called “browning” and, along with catecholamine-
stimulation in cold temperatures, many stimuli have been claimed to “brown” 
WAT (60). The browning of WAT is an active area of investigation because beige 
adipocytes increase energy expenditure and improve metabolic health in rodents 
(48). Additionally, studies have shown that humans contain cells with a beige 
gene signature and that these cells are correlated with reduced BMI and insulin 
sensitivity (53,54,61). As such, beige adipocytes may prove useful for weight loss 
therapy in humans.  
Function 
Adipose tissue as an endocrine organ 
 The adipose tissue secretes a number of factors termed adipokines that 
modulate whole body metabolism (62). Two of these potent signaling factors are 
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adiponectin and leptin. Adiponectin is considered a beneficial adipokine that 
promotes insulin sensitivity (63). Its overexpression in mice promotes healthy 
adipose tissue expansion (64). Adiponectin levels negatively correlate with BMI 
and insulin resistance (63). Leptin is largely produced by WAT and is a hormone 
that is required for satiety; it inhibits food intake, along with altering energy 
expenditure, angiogenesis and sexual maturity (62). Leptin levels are increased 
with BMI in humans and obesity is often associated with leptin resistance (65,66).  
Lipid Handling 
 WAT is a critical energy storage organ; thus, many of the signaling 
pathways of the adipocyte control storage and breakdown of lipids (Figure 1.2). 
Like liver, WAT converts protein or carbohydrate metabolites into stored lipids 
through the process of DNL (67). Additionally, adipocytes can directly uptake 
circulating lipids from chylomicrons for storage as TGs (68).  
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Figure 1.2 Lipid metabolism in adipose tissue 
 
 
 
FIGURE 1.2 Lipid metabolism in adipose tissue. Adipose tissue processes 
and stores fatty acids as triglyceride (TG) in lipid droplets. These fatty acids can 
come from a variety of sources, including the diet, very low-density lipoprotein 
(VLDL) particles released by the liver, or direct synthesis from glucose via de 
novo lipogenesis. Triglycerides can be broken down via lipolysis and released 
into circulation to be taken up by other tissues, such as muscle liver or pancreas. 
Additionally, fatty acids liberated by lipolysis can be re-esterified into triglyceride 
or oxidized by the mitochondria. TG; triglyceride, VLDL; very low-density 
lipoprotein. 
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De novo lipogenesis 
 DNL in the adipocyte is defined by a well-characterized metabolic pathway 
with identical enzymes to hepatic DNL (67). Although the pathways and enzymes 
of adipose tissue and liver DNL are identical, experimental evidence suggests 
adipose tissue and liver DNL may be differentially regulated and serve distinct 
functions. For instance, obesity increases hepatic DNL and decreases adipose 
tissue DNL in mice and humans (69-73). In humans, increased hepatic DNL is 
associated with insulin resistance, hepatic steatosis and increased adipocyte 
size, while increased adipose tissue DNL is negatively correlated with these 
measures (74-77). In adipocytes, glucose, a major substrate for DNL, is 
transported into the cell by the adipocyte-specific transporter, Glut4 (78). As in 
liver, SREBP1 and ChREBP are the two transcription factors that control 
expression of most genes required for DNL. They are activated by both glucose 
and insulin, coupling them to overall metabolic homeostasis (79). Although FA 
uptake and esterification of circulating dietary lipids account for most of stored 
TGs, DNL may be required for the synthesis of key signaling lipids (80-82). For 
instance, DNL in adipocytes may be involved in synthesizing endogenous ligands 
for PPAR (82,83), a master regulator of adipogenesis, and DNL in hepatocytes 
may be involved in synthesizing endogenous ligands for PPAR (80,81,84). 
While eicosanoids and poly unsaturated FAs activate PPAR in vitro (85-87), the 
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hypothesized endogenously synthesized ligands have yet to be specifically 
identified in vivo (84). 
Lipolysis  
 Conversely, lipolysis is the breakdown of triglycerides (TGs) into FAs and 
glycerol. Lipolysis usually occurs during fasting; it liberates FAs to fuel muscle 
and liver. Briefly, -adrenergic receptor stimulation, usually by catecholamines, 
activates GTP stimulatory (Gs) proteins, which in turn activate adenylyl cyclase 
(AC), increasing the concentration of cyclic AMP (cAMP). This activates Protein 
Kinase A (PKA), which phosphorylates lipases and other proteins, including lipid 
droplet proteins, some of which will be detailed below (88). A previous prevailing 
hypothesis suggested that one lipase, hormone sensitive lipase (HSL) was 
responsible for majority of TG hydrolysis; this hypothesis was challenged when 
HSL null animals did not display lipolytic defects or major alterations in obesity, 
but accumulated DGs in adipose tissue, muscle and testis (89-91). Animal 
studies identified an additional lipase termed adipose triglyceride lipase/desnutrin 
(ATGL) and suggest that it is the major TG lipase in adipocytes (92-94). These 
studies were later confirmed when human ATGL mutations were discovered and 
characterized (95-98); these will be discussed in detail later in the chapter. Thus, 
in adipocytes there are three identified lipases that coordinate the breakdown of 
a molecule of TG into three molecules of FA and one molecule of glycerol. 
Adipose triglyceride lipase (ATGL) catalyzes the primary reaction and hydrolyzes 
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TG to diacylglycerol (DG) (92-94). Hormone sensitive lipase (HSL) preferentially 
hydrolyzes DG to monoacylglycerol (MG). Finally, monoglyceride lipase (MGL) 
hydrolyzes MGs (99). FAs are then transported to other tissues, such as liver and 
muscle for fuel or re-esterified into TG at the LD. Synthesis of glycerol 3-
phosphate from glucose or pyruvate via glyceroneogenesis controls the rate of 
FA re-esterification (100). Lipase binding partners will be discussed later in the 
chapter.  
Thermogenesis 
 Although brown adipocytes also perform DNL and lipolysis to store lipids, 
their primary function is to generate heat through nonshivering thermogenesis. 
Thus, brown adipocytes have a specific gene expression signature in order to 
perform this task. PR Domain Containing 16 (Prdm16), C/ebp, Pgc1, Early B-
Cell Factor 2 (Ebf2), and peroxisome proliferator activated receptor alpha 
(PPAR are transcription factors that are required for brown adipocyte identity 
and the thermogenic gene program (48). Prdm16 activates the transcription of 
genes important for BAT function, including uncoupling protein-1 (UCP1), the 
protein responsible for thermogenesis through uncoupling of oxidative 
phosphorylation (101). UCP1 is located in the mitochondrial membrane and 
uncouples the electron transport chain by facilitating a proton leak, which 
generates energy in the form of heat (102). UCP1 protein steadily increases with 
the differentiation of brown adipocytes (103) and without it, mice become cold-
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sensitive when housed at room temperature (20-23°C) (104) and obese when 
housed at thermoneutrality (30°C) (105), a temperature that eliminates thermal 
stress. Although certain adult human BAT depots are more similar in appearance 
and gene expression signature to rodent beige cells (106), cold exposure in 
humans still promotes glucose and FA uptake in BAT (107); this uptake is 
correlated with leanness (108). Furthermore, cold exposure in humans leads to 
increases in insulin sensitivity and energy expenditure (61,109). Taken together, 
this evidence suggests that humans indeed have functional BAT and that 
activating this BAT can improve metabolic health.  
 Beige/brite adipose tissue function and gene expression overlaps with 
both WAT and BAT. Beige/brite cells also express the transcription factors 
Prdm16, C/ebp, and Pgc1 (101). UCP1 is also expressed, but not nearly to the 
extent of BAT (60). The markers that are uniquely beige/brite include Cd137, 
Tbx1, Tmem26, Cited1, and Shox2 (48). The current contributions of beige/brite 
cells to metabolism, particularly in humans, are unclear, but current knowledge 
suggests that they have therapeutic potential.  
The insulin/glucagon axis  
 Insulin is an anabolic hormone that is secreted by the -cells of the 
pancreatic islet in response to postprandial blood glucose and amino acid (AA) 
increases (110-112). Among its primary effects is to stimulate glucose clearance 
from circulation. Numerous tissues contain insulin receptors, including adipose 
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tissue, muscle, and liver. In liver, insulin binds to insulin receptors, which recruit 
and phosphorylate substrate adaptors, such as the insulin receptor substrates 1 
and 2 (IRS1/2) (113,114). IRS 1/2 bind Phosphoinositide 3-kinase (PI3K), which 
generates the lipid second messenger phosphatidylinositol-3,4,5-triphosphate 
(PIP3), thereby activating  3-phosphoinositide-dependent protein kinase 1 (PDK1) 
and, in turn, activating isoforms of Protein Kinase B (PKB/AKT) (115,116). This 
node of the insulin signaling pathway is critical for metabolic responses to insulin. 
The PI3K/Ras-mitogen-activated protein kinase (MAPK) signaling node controls 
insulin-responsive differentiation and growth and will not be discussed in detail 
here (117). AKT is a kinase with critical downstream functions, such as 
preventing hepatic gluconeogenesis through FOXO1 inhibition, activating 
glycogen synthesis through Glycogen synthase kinase 3 (GSK3), promoting 
glucose uptake via Akt substrate of 160 kDa (AS160), and enhancing protein 
synthesis via Mammalian target of rapamycin (mTOR) (118). Additionally, Insulin 
induces FA and TG synthesis by activating the key lipogenic transcription factors 
SREBP1, USF1 and LXR (117).   
 Conversely, glucagon is a catabolic hormone secreted by the -cells of 
the pancreatic islet in response to fasting, low blood glucose levels, and 
increases in circulating FAs and AAs (119). Glucagon binds to the Glucagon 
receptor (GCGR), a g-protein coupled receptor (120), which activates the 
stimulatory g protein alpha (Gs) subunit. Gs activates AC, increasing the 
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generation of the second messenger cAMP and activating PKA (121). PKA 
stimulates both hepatic glycogenolysis and gluconeogenesis. PKA also blocks 
DNL by direct inhibition of ACC phosphorylation and by reduction of pyruvate 
levels (20). Thus, insulin and glucagon exert opposing functions to maintain 
euglycemia. 
 
Lipid deposition in disease 
 Two organs that function as master regulators of lipid synthesis and 
storage are the liver and adipose tissue. In healthy animals, both liver and 
adipose tissue synthesize lipids to be stored in largely in white adipose tissue. In 
times of caloric excess, these processes become dysregulated; one hypothesis 
suggests that adipose tissue reaches its storage capacity and lipids are 
ectopically deposited in other organs such as liver, muscle, and pancreas, which 
may result in metabolic disease. Thus, the second part of chapter 1 will focus on 
the roles of liver and adipose tissue in lipid deposition in disease.     
Liver Dysfunction 
 The liver is a master regulator of whole body glucose metabolism. It 
maintains blood glucose levels by alternating between catabolic and anabolic 
signaling pathways. Chronic exposure of humans or rodents to high calorie diets 
leads to obesity, which is often associated with steatosis, insulin resistance, and 
derangements in hepatic metabolic signaling. 
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Obesity/Insulin Resistance  
 Chronic caloric excess leads to obesity, which promotes derangements in 
liver metabolism, although the mechanisms for this are multifactorial, complex, 
and far from clear. Obesity is characterized by hyperglycemia, hyperinsulinemia, 
and dyslipidemia (122). Glucose, insulin, and FAs are critical for the regulation of 
liver metabolism. Thus, prolonged exposure of hepatocytes to these three 
signaling molecules has deleterious consequences.  
 Glucose activates hepatic DNL. As such, chronic exposure to high levels 
of circulating glucose strongly upregulates key lipogenic transcription factors 
SREBP1, ChREBP, and induces the expression of the adipogenic transcription 
factor, Peroxisome proliferator-activated receptor gamma (PPAR), further 
promoting hepatic lipid deposition (123). Hyperglycemia, by upregulating DNL, 
also indirectly promotes liver vLDL release, increasing plasma TG levels (124). 
High glucose levels also increase hepatic TG content by decreasing 
mitochondrial -oxidation (125).  
 Hyperinsulinemia is detrimental because when the liver is exposed to high 
insulin levels, insulin signaling components are downregulated, promoting 
hepatic insulin resistance (126). Additionally, hepatic insulin resistance promotes 
dysregulated hepatic gluconeogenesis as insulin no longer suppresses 
gluconeogenic genes, leading to uncontrolled glucose production by the liver, 
furthering hyperglycemia (126,127). The cause of this dysregulated hepatic 
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gluconeogenesis is unclear, but one hypothesis suggests that uncontrolled 
adipose tissue lipolysis raises hepatic acetyl-coA levels and promotes PC 
activation to facilitate hepatic glucose production (28). Circulating FAs, often 
stemming from uncontrolled adipose tissue lipolysis, can promote hepatic lipid 
deposition and general hepatocyte dysfunction (128). An excess of long-chain 
FAs can lead to formation of peroxidated lipids and reactive oxygen species 
(ROS) by peroxisomes in the hepatocyte (129). Fatty liver and its associated 
metabolic derangements often lead to T2D, although, in rare cases the two can 
be dissociated (130). 
The spectrum of NAFLD 
 Hepatocytes rarely store lipids except during fasting or obesity (11). Non-
alcoholic fatty liver disease (NAFLD) refers to a liver disease spectrum which 
begins with benign and reversible TG accumulation, often due to excess caloric 
intake (131). Prolonged exposure of hepatocytes to lipotoxic FAs leads to 
hepatocyte ballooning and death, activating KC and promoting inflammatory 
cascades, progressing to non-alcoholic steatohepatitis (NASH). Chronic 
inflammation activates HSCs, promoting fibrosis and transitioning the disease to 
cirrhosis. Prolonged cirrhosis can progress to hepatocellular carcinoma (132).  
Adipose tissue dysfunction 
Obesity  
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 Healthy adipose tissue expansion is critical for metabolic health. One 
hypothesis suggests that during chronic overfeeding, adipose expands until its 
capacity is reached; expanded adipose tissue is characterized by increased 
fibrosis, and inflammation (133,134). Inflamed adipocytes secrete 
chemoattractant proteins, such as monocyte chemoattractant protein 1 (MCP1), 
which recruit macrophages to clean up dying adipocytes (122). Chronically 
inflamed expanded adipose tissue is also characterized by dysregulated lipid 
signaling. For instance, obesity results in uncontrolled adipocyte lipolysis, which 
causes increases in circulating FAs and ectopic TG deposition in other tissues, 
such as liver and muscle (135,136). Increases in serum FAs induce insulin 
resistance in human subjects (137). Chronic inflammation has also been 
correlated with insulin resistance (133,138-140). Under conditions of chronic 
obesity, insulin fails to stimulate glucose uptake into tissues, leading to 
hyperinsulinemia and high glucose in the blood, which are associated with type 2 
diabetes (T2D) (122).  
Lipodystrophy 
 Metabolic disease can occur when an excess of adipose tissue is present. 
Interestingly, similar metabolic derangements develop with too little adipose 
tissue. Lipodystrophy is a rare, often monogenic disorder, characterized by 
partial or generalized adipose tissue deficiency (141). Humans and mice that lack 
adipose tissue develop fatty liver, hyperlipidemia, and severe insulin resistance 
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(142). These cases emphasize the importance of proper FA storage for the 
maintenance of metabolic health. Furthermore, lipodystrophic humans and mice 
are often lacking beneficial adipokines secreted by the adipose tissue, such as 
adiponectin and leptin, leading to insulin resistance and hyperphagia (141).  
 
Other Metabolic Tissues: Muscle and Pancreas 
 In addition to liver and adipose tissue, other tissues are critical for the 
maintenance of metabolic homeostasis. Skeletal muscle largely consumes 
postprandial glucose, provides a protein reservoir during starvation, and 
develops insulin resistance. The pancreas is a critical exocrine and endocrine 
organ that is dysregulated during obesity. The structure and function of skeletal 
muscle and pancreas are detailed below. 
Structure and Function 
Skeletal Muscle 
 Skeletal muscle is an organ that is critical for both locomotion and 
metabolism. Muscle consists of multi-nucleated, post mitotic myofibers that are 
synthesized from fused myocytes. Additionally, muscles contain satellite cells, 
which are stem cells (143). Skeletal muscle largely functions to generate force 
and provide structural stability. As these actions are energetically expensive, 
skeletal muscle consumes a substantial nutrients and is responsible for 75% of 
the body’s glucose clearance; skeletal muscle also stores glycogen and utilizes 
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FAs liberated from AT (144). Like liver and adipose tissue, skeletal muscle 
contains insulin receptors that promote insulin-stimulated glucose uptake via the 
glucose transporter Glut4 (145). Additionally, as muscle fibers contain 50-75% of 
the body’s total protein, they provide a protein reservoir during starvation (146). 
Muscles fibers can be divided into three classes based on their metabolism; 
class I is oxidative, class IIA is intermediate, and class IIx is glycolytic (146). 
Pancreas 
 The pancreas is divided into two distinctly functioning parts: the exocrine 
pancreas and the endocrine pancreas. The exocrine pancreas is a part of the GI 
system and contains the duct cells, acinar cells, and associated connective 
tissue. It largely synthesizes and secretes digestive enzymes into the intestine 
(147). The endocrine pancreas consists of the islets of Langerhans (islets), which 
contain glucagon-secreting  cells (15%), insulin-secreting  cells (80%), and 
somatostatin-secreting  cells (5%) (147,148). The islets comprise 1-2% of the 
adult pancreas in most mammals and hormones synthesized and secreted by 
islet cells modify whole body homeostasis (147). The roles of insulin and 
glucagon are detailed above. Somatostatin inhibits both glucagon and insulin 
release (149). 
Dysfunction 
Skeletal Muscle 
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 Typically, healthy skeletal muscle contains minimal TG (.5%) stored in 
cellular LDs, although endurance athletes demonstrate much larger lipid stores, 
known as the athlete’s paradox (150). However, during obesity, an excess of 
circulating FAs become deposited in skeletal muscle and lead to a substantial 
increase in TG content (3.5%) (151). Obesity promotes skeletal muscle insulin 
resistance and hyperlipidemia has been suggested to exacerbate this (152), 
although the mechanism for this is far from clear. Insulin resistance alters insulin-
stimulated glucose uptake in muscle, and as muscle is such a critical organ for 
glucose disposal, muscle insulin resistance is considered to be a substantial 
contributor to T2D (153). Lipodystrophy, as it is a disease of reduced TG storage 
capacity, leads to similar pathologies and comorbidities in muscle as obesity 
(141).  
Pancreas 
 As peripheral tissues develop obesity-related insulin resistance and the 
circulation becomes hyperglycemic, the pancreas increases insulin secretion, 
leading to hyperinsulinemia. In the short-term, elevated insulin production can 
lead to -cell hypertrophy (154). Both hyperglycemia and chronic augmentation 
of insulin production are correlated with increased ER stress and -cell death, 
which may then cause overt diabetes (155). Additionally, increases in circulating 
FAs can lead to ectopic lipid deposition in pancreas, further promoting pancreatic 
dysfunction (156).   
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Part 2: Lipid Droplets as Dynamic Organelles 
 Organs such as liver and adipose tissue are master regulators of lipid 
metabolism. Hepatocytes and adipocytes, as do all cells, store cytotoxic FAs as 
neutral lipids in organelles termed LDs. Although once considered inert lipid 
storage vesicles, research from the past 20 years suggests that LDs are dynamic 
organelles that possess a unique proteome and numerous related signaling 
pathways. LDs are also highly integrated into cellular metabolism and its 
associated signaling pathways. Furthermore, LD proteins are critical for lipid 
homeostasis, as humans or mice with LD protein mutations manifest severe 
metabolic dysfunction. The LD structure, function, and its proteome will be 
discussed in detail below. 
Structure, Formation and Prevalence 
 The LD is an organelle that functions in the storage of neutral lipids. It 
consists of a neutral lipid core, which typically contains a mixture of TGs and 
cholesterol esters (CE), surrounded by a phospholipid (PL) monolayer. 
Numerous identified proteins, some of which are cell-type specific, are 
associated with or embedded in this monolayer and are called LD proteins (157). 
Their functions will be described in detail below. LDs are very heterogeneous 
organelles, differing in their size, protein coat, and also their lipid composition 
(158).  
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 The exact mechanism by which LDs are formed is not known, but it is 
hypothesized that they form from a lipid lens in the ER bilayer (159). Numerous 
hypothetical LD biogenesis models have emerged from more recent 
experimental evidence. One hypothesis proposes a model based on the principle 
of oil dewetting (160). This model suggests that a lipid lens forms in the ER 
bilayer by the favorable reduction of the contact angle of the lipids with the 
bilayer surface. The LD then buds off due to thermodynamically favorable 
reduction of surface tension. Another hypothesis proposes a synchronized, step-
wise model (161) that suggests that FA synthesis in the ER promotes TG 
enrichment, PL synthesis, and “globule formation”. As the “globule” transitions to 
a nascent LD, the ER membrane bends and proteins are recruited to promote 
curvature until a nascent LD is formed. Whether or not LDs permanently retain 
their ER connection is still unclear. Additional experiments are needed to further 
elucidate the true mechanism of LD biogenesis.   
 Numerous proteins appear to coordinate LD formation at the ER by 
activating FAs, synthesizing neutral lipids, or synthesizing PLs for rapidly 
expanding nascent droplets (161). Two additional ER-resident proteins that  may 
play a more structural role in LD formation are Seipin and Fat storage-inducing 
transmembrane protein (FIT/FITM) (161). Seipin localizes to ER-LD junctions 
(162). Although the precise role of Seipin in this process is far from clear, Seipin-
deficient cells display aberrant LD size and number (162,163), while 3T3-L1 
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adipocytes deficient for FIT2 display reduced LD size and number (164). 
Interestingly, deletion mutants of all of the currently identified proteins alluded to 
above suggest redundancy in the system, as no single protein is required for LD 
biogenesis (161).  
 All cells store neutral lipids in LDs, but adipose tissue is specifically 
adapted to store large quantities of TGs. LDs in white adipocytes can reach up to 
100M in diameter, relegating other cellular components to the periphery of the 
cell, and each adipocyte in WAT is typically unilocular (165). Moreover, LDs in 
non-adipocyte cells are multilocular, much smaller (1-10M), and more distant 
from the cell surface, although they can increase in size in steatotic tissues, such 
as liver and muscle (166).  
Function 
 A primary function of LDs is to store cytotoxic FAs in the form of inert TGs. 
While LDs in the adipocyte provide long-term TG storage, other cells, such as 
hepatocytes and myocytes, form LDs much more transiently to facilitate their 
metabolism (166). Regardless, LDs are highly responsive to lipogenic and 
lipolytic signaling (167), which will be discussed in detail below. LDs also appear 
to play a critical role in immune cell function, synthesizing inflammatory signaling 
lipids and facilitating antigen cross-presentation (168). Furthermore, LDs are 
present in cancer cells and are associated with poor prognosis in human breast, 
prostate, and colon cancers (169). In addition to their metabolic functions, LDs 
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possess critical alternative functions. For instance, they sequester excess 
proteins (170), such as maternal histones in Drosophila embryos (171). They are 
also required for the replication cycle of certain viruses, such as the Hepatitis C 
Virus (172). Thus, research continually proves that LDs are not inert, fat storing 
organelles, but dynamic, multi-functional signaling bodies.  
The LD Proteome 
The PAT family 
 The PAT family, named for its three founding members Perilipin, 
Adipophilin, and Tail-interacting protein of 47 kDa (Tip47), is one of the most 
abundant families of LD proteins. The PAT family currently contains five 
members numbered chronologically based on their discovery and most share a 
common N-terminal PAT domain of yet unknown function (173). Perilipins are 
present in vertebrates and insects their expression promotes lipid deposition 
(174). Each member possesses unique functions and tissue-specific distribution, 
which will be detailed below. 
Perilipin 1 
 Perilipin 1 was first characterized as a highly phosphorylated protein in the 
adipocyte fat cake (lipid fraction of the adipocyte) (175). It is expressed in mature 
white and brown adipocytes (175-177) and to a lesser extent in steroidogenic 
cells (178). Alternative splicing of the Perilipin 1 transcript produces three 
isoforms, termed Perilipin A-C. Perilipin A is the most abundant isoform in 
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adipocytes and murine Perilipin A contains 517 AAs. Perilipin B is less abundant 
and contains 422 AA in mice, 405 of which are shared with Perilipin A (175,176). 
The shortest isoform, Perilipin C is solely expressed in steroidogenic cells 
(178,179). As Perilipin A is highly abundant and the most-characterized of the 
Perilipin isoforms, it will be the isoform referred to as Perilipin 1 and discussed in 
the remainder of this work. Its expression steadily increases with adipogenic 
differentiation and it promotes lipid deposition by inhibiting lipolysis (180-182). 
This function will be detailed below.  
Perilipin 2/Adipose differentiation-related protein (ADRP)/Adipophilin (ADFP)  
 Perilipin 2 demonstrates the most ubiquitous expression pattern of the 
PAT family members. As it is unstable in the cytoplasm, it is constitutively 
localized to LDs (183,184). Perilipin 2 was first characterized as an mRNA with 
100-fold induction upon adipogenic differentiation (185). It coats nascent LDs and 
is subsequently replaced by Perilipin 1 as these LDs mature (183,186). In 
addition to adipocytes, Perilipin 2 localizes to LDs in most other cell types (187). 
In the absence of Perilipin 1 or during lipolytic stimulation, Perilipin 2 coats 
mature LDs, but inhibits lipolysis less effectively (177,188). 
Perilipin 3/Tip47 
 Perilipin 3 was initially identified in a yeast two hybrid screen as a 
mannose 6-phosphate receptor binding protein (189). Similar to Perilipin 2, it is 
ubiquitously expressed and localizes to LDs in most tissues. Unlike Perilipin 2, 
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Perilipin 3 has cytoplasmic stability (190,191). Its partial crystal structure 
suggests this stems from a C-terminal bundle of 4 amphipathic helices that are 
structurally similar to Apopliprotein E (ApoE). These helices can remain closed 
and soluble in solution or open and embed in PLs (192). As the two most similar 
PAT members, Perilipin 2 and Perilipin 3 share 43% sequence similarity (173). 
Perilipin 4/S3-12 
 Perilipin 4, like other PAT members, was identified as a protein highly 
induced during adipocyte differentiation (193). It largely coats nascent LDs in 
white adipocytes, but is also expressed to a lesser extent in muscle and heart 
(186,194). At 160 kDa, Perilipin 4 is the largest of the PAT proteins and the only 
member that lacks the N-terminal PAT domain (191). Perilipin 4 and Perilipin 1 
are least similar to other PAT family proteins (173). 
Perilipin 5/PAT family member expressed in oxidative tissues 
(OxPAT)/Myocardial LD Protein (MLDP)/LD Storage Protein 5 (LSDP5) 
 Perilipin 5 is most highly expressed in oxidative tissues, such as heart and 
skeletal muscle, while lower levels are expressed in liver, WAT and BAT, testis, 
and adrenal gland (195-197). Like Perilipin 3, Perilipin 5 is stable both on LDs 
and in the cytoplasm (195).  
 The CIDE family 
 The cell death-inducing DNA fragmentation factor 45-like effector (CIDE) 
family of LD proteins shares sequence homology with the DNA fragmentation 
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factor 45, a factor cleaved by caspase 3 during apoptosis (198,199). There are 
currently three identified CIDE family proteins and all share a common CIDE 
domain at their N-terminus (200). Although originally thought to promote cell 
death (198,199,201), these proteins dually localize to LDs and the ER and 
promote lipid deposition with their expression (200,202). Their tissue distribution 
and functions will be detailed below. 
Cidea 
 Murine Cidea is highly expressed in brown adipocytes, to a lesser extent 
in white adipocytes, and expressed at much lower levels in heart, brain, skeletal 
muscle, lymph nodes, thymus, appendix, and bone marrow (198,203).  It is highly 
induced upon adipogenic differentiation (203) and its expression in human WAT 
is correlated with insulin sensitivity in obese humans (204,205). Although 
originally found to be localized to mitochondria (201,203), Cidea also localizes to 
LDs (204). In addition to its other tissue specificity, Cidea coats LDs in steatotic 
liver (206) and in the lactating mammary gland (207).  
Cideb 
 Cideb is expressed in liver, kidney, and the small intestine (198). It 
localizes to the ER and LDs and is necessary for hepatocyte vLDL lipidation and 
cholesterol homeostasis (208-210). Cideb interacts with ApoB-100 to facilitate 
the TG-enrichment of vLDL particles (209). Cideb may also play a role in foam 
cell formation, as it is highly upregulated in lipid-laden macrophages (211).  
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Cidec/Fsp27 
 Fsp27 was identified as an mRNA whose expression is highly induced 
during adipogenic differentiation (212). It is specific to brown and white 
adipocytes (203,213), although its expression is massively induced in steatotic 
liver and lipid-filled macrophages (211,214). Similar to Cidea and Perilipin 1, its 
expression in WAT is also correlated with insulin sensitivity in obese humans 
(204).  Fsp27 promotes the formation of unilocular adipocytes and Fsp27-
deficient 3T3-L1 adipocytes display reduced TG content and LD number (215). 
Both Cidea and Fsp27 localize to LD-LD contact sites (LDCS), suggesting that 
they function in LD fusion (216,217). Interestingly, Fsp27 physically interacts with 
Perilipin 1 to promote LD fusion (218).  
 
LD Proteins and Signaling 
 LD proteins are variable in their tissue-specificity and function and play 
integral parts in the dynamic signaling of the LD. Their diverse functions are still 
an active area of investigation and known functions range from inhibiting lipases 
to localizing LDs to microtubules. Some roles of specific LD proteins in LD 
signaling are detailed below.  
Lipolysis 
 ATGL, HSL, and MGL are the three lipases that are demonstrated to be 
critical for TG breakdown at the adipocyte LD. Mouse knock out models 
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demonstrate the importance of LD proteins in regulation of lipolysis. Animals 
deficient in Perilipin 1 (177), Perilipin 5 (219), Cidea (203), and Fsp27 (220) all 
display increased lipolysis. Additionally, two LD-bound ATGL cofactors, 
Comparative gene identification 58 (Cgi-58)/α/β hydrolase domain-containing 
protein 5 (ABHD5) (an activator) (221) and G(0)/G(1) switch gene 2 (G0S2) (an 
inhibitor) (222) have been identified. Animals deficient in these proteins also 
demonstrate altered lipolysis (223-225). Although the mechanisms whereby 
these proteins inhibit lipolysis are often unclear, some mechanisms have been 
established by experimental evidence and will be detailed below.  
 Perilipin 1 was originally identified as a highly phosphorylated protein in 
the fat cake of isoproterenol (-adrenergic agonist) -treated adipocytes (175) 
Rodent Perilipin A contains six PKA phosphorylation sites, which are 
phosphorylated during -adrenergic stimulation (175,182,226,227). In 
unstimulated adipocytes, Perilipin 1 localizes to LDs and binds Cgi-58, 
sequestering it away from ATGL (228). Upon lipolytic stimulation, PKA 
phosphorylates both Perilipin 1 and HSL (229-231). HSL then translocates to the 
LD (232-234), where Perilipin 1 dissociates from Cgi-58 and docks and binds 
phosphorylated HSL to facilitate stimulated lipolysis (235-237) (Figure 4.1). 
 Perilipin 5 is the currently the sole PAT family member that inhibits 
lipolysis by directly interacting with both Cgi-58 and ATGL at the LD (238,239). 
This interaction is dependent upon the 64 C-terminal AAs of Perilipin 5 (238). 
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PKA also phosphorylates Perilipin 5 upon lipolytic stimulation, suggesting that it 
may function similarly to Perilipin 1, but in oxidative tissues (239). In human 
adipocytes, AA 120-220 of Fsp27 interact with ATGL, suggesting that Fsp27 may 
promote TG deposition by inhibiting lipase activity (240).   
 In an additional layer of lipolytic regulation, LD Proteins also function as 
substrates for chaperone-mediated autophagy (CMA), which is the lysosomal 
degradation of certain cellular protein components. CMA often takes place during 
nutrient deprivation. During starvation, both Perilipin 2 and 3 bind heat shock 
cognate protein of 70 kDa (Hsc70) and are degraded by CMA to facilitate the 
activation of lipolysis in mouse hepatocytes (241). 
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Figure 1.3 Lipolysis in the adipocyte 
 
FIGURE 1.3 Lipolysis in the adipocyte. Catecholamines activate the 3 adrenergic 
receptor (3AR), causing the stimulatory G protein (Gs) to dissociate from the inhibitory G 
protein (Gi). Gs activates adenylyl cyclase, which increases cAMP levels and activates 
protein kinase A (PKA). PKA phosphorylates Perilipin 1 (Plin1) and Hormone sensitive 
lipase (HSL), causing Plin1 to dissociate from Comparative gene identification 58 
(Cgi58) and interact with HSL at the lipid droplet. Cgi58 binds and activates Adipose 
triglyceride lipase (ATGL), which breaks down triglyceride (TG) to diglyceride (DG). HSL 
breaks down DG to monoglyceride (MG) and Monoglyceride lipase (MGL) breaks down 
MG to fatty acid (FA) and glycerol.  
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LD Trafficking 
 The cellular trafficking of LDs is not well-understood, but recent data 
suggests that aqueous vesicle transportation machinery localizes to the LD 
during FA stimulation. Both Rab and SNARE proteins localize to LDs during 
oleate stimulation (167). Upon oleate loading in a cardiomyocyte cell line, 
SNARE complex proteins localized to LDs and physically interacted with Perilipin 
2 (242). Additionally, microtubules are necessary for LD movement, as 
nocodozole treatment prevents LD fusion (243). In flies, dynein, a microtubule 
minus end motor, localizes to LDs and physically interacts with Perilipin 2 (243). 
Inhibiting dynein reduced LD formation, suggesting that it is necessary for LD 
formation and potentially LD fusion.  
LDs and Human Disease 
Insight from animal models 
 Animal models with PAT and CIDE protein deficiencies have been 
extensively characterized. These animals point toward critical functions for LD 
proteins in metabolic disease pathology. A brief summary of some of the 
published animal work is presented below and summarized in Table 1.1. 
Perilipin 1 
 A Perilipin 1 null mouse was derived by targeted deletion of exons 4-6 
(177). As Perilipin 1 is critical for LD deposition in adipocytes, Perilipin 1 null 
animals had greatly reduced adipose tissue weight and adipocyte size due to 
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increases in basal lipolysis. Interestingly, levels of stimulated lipolysis were vastly 
decreased in mutant adipocytes, suggesting that Perilipin 1 is required for 
stimulated-lipolysis. Knockouts were glucose intolerant and were resistant to diet-
induced obesity, but not diet-induced glucose intolerance.   
Perilipin 2 
 Perilipin 2 null mice were generated by two separate groups (244,245). 
Chang et al. generated Perilipin 2 null mice by targeted removal of exons 2 and 
3, which was later shown to produce truncated, but functional Perilipin 2 in the 
murine mammary gland (246). To circumvent this problem, McManaman et al. 
generated new Perilipin 2 null mice by targeted removal of exon 5 (245). Perilipin 
2 null animals from both groups demonstrated reduced hepatic steatosis. 
Additionally, the Perilipin 2 null mice generated by McManaman et al. (245) 
showed resistance to diet-induced obesity and improved glucose tolerance. 
Perilipin 2 null animals had reduced adipose tissue inflammation and increased 
Ucp1-positive beige/brite adipocytes in their iWAT. They also had increased 
activity and food consumption.  
Perilipin 5 
 A Perilipin 5 null mouse was generated by targeted deletion of exons 1-4 
(219). Although Perilipin 5 null animals displayed a beneficial reduction in 
myocardial lipids and an increase in oxidation, they also showed damaging 
increases in myocardial ROS. Despite this, streptozotocin-treated diabetic 
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Perilipin 5 null animals were protected from diabetes-induced heart malfunction 
(247).    
Cidea 
 A Cidea null mouse was derived by targeted deletion of the part of the first 
intron and the second exon of the Cidea gene (203). Cidea null mice 
demonstrated reduced adipose tissue weight and increased BAT lipolysis. During 
cold exposure, null animals had increased metabolic rate and body temperature, 
which may stem from a physical interaction between Cidea and the mitochondrial 
uncoupler Ucp1 (203). 
Cideb 
 A Cideb null mouse was generated by targeted removal of exons 3-5 
(208). Cideb null animals were resistant to diet-induced obesity, glucose 
intolerance, and hepatic steatosis. They had reduced serum TGs, FFAs, 
concomitant with increased hepatic FA oxidation and increased serum 
adiponectin. Their overall metabolism was increased and lipogenic genes in the 
liver were decreased. Interestingly, Cideb mice had increased liver TGs in the 
chow-fed condition due to reduced hepatic secretion of vLDL particles (209). 
vLDL particles secreted by the livers of the Cideb null mice  had normal levels of 
ApoB-100, but reduced TG levels, suggesting that Cideb is necessary for vLDL 
particle lipidation (209). 
Cidec/Fsp27  
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 Groups have generated global and tissue-specific Fsp27 null animals. 
Global Fsp27 null animals were created by targeted deletion of exons 1 and 2 
(220). Fsp27 null animals demonstrated a very significant reduction in WAT 
weight. Adipocytes from these animals had multilocular LDs and had increased 
basal and stimulated lipolysis. Fsp27 null animals were resistant to diet-induced 
obesity and demonstrated improved glucose tolerance at 23°C. When Zhou et al. 
housed Fsp27 null animals at 30°C to remove thermogenic stress, they more 
closely phenocopied lipodystrophic humans and had both reduced weight gain, 
increased hepatic TG, and reduced glucose and insulin tolerance (248).  
 Animals with an adipose tissue-specific Fsp27 deficiency (Fsp27AtKO) 
were generated using Cre/loxP technology. Fsp27 fl/fl mice were crossed to an 
adipose tissue-specific AP2-cre (249). Similar to Fsp27 null animals, Fsp27AtKO 
animals also had reduced adipose tissue weight and multilocular adipocytes, with 
concomitant increases adipocyte lipolysis and hepatic steatosis. These animals 
were more glucose intolerant compared with controls in high fat-fed conditions. 
Additionally, liver-specific knockdown of Fsp27 in db/db mice reduced liver TGs, 
further cementing the idea that Fsp27 expression promotes lipid deposition (214).  
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Table 1.1 LD proteins of the PAT and CIDE families. Tissue specificity and 
some knock out animal models of the PAT and CIDE family LD proteins are 
briefly described below. Tissues listed in bold text are those with highest gene 
expression. Abbreviations: N/A, not applicable; BAT, brown adipose tissue; WAT, 
white adipose tissue; ROS, reactive oxygen species; ↑, increased; ↓, decreased. 
Numbers correspond to primary references of the animal model work. 
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Human Mutations 
 Rare human mutations in LD proteins are associated with metabolic 
disease, thus promoting the idea that LD protein dysfunction can underlie 
metabolic disease pathology (142). Some of these mutations are detailed below 
and can be separated into a few different classes: 1) neutral lipid storage disease 
(NLSD), which results in lipid storage in locations other than adipose tissue, 2) 
familial partial lipodystrophy (FPL), which is a rare, inherited partial loss or 
redistribution of adipose tissue, or 3) congenital generalized lipodystrophy (CGL), 
which is a rare, inherited full loss of adipose tissue (142). 
Perilipin 1 
 Perilipin 1 is the prominent LD protein in mature white adipocytes and 
functions to prevent unstimulated lipolysis and facilitate stimulated lipolysis 
(175,177,181). Thus, humans with reduced Perilipin 1 function manifested 
lipodystrophy, fatty liver, and metabolic syndrome. Two heterozygous frameshift 
mutations in the C-terminus of Perilipin 1 were identified in three separate 
families. These mutations resulted in autosomal dominant FPL, dyslipidemia, and 
diabetes, most likely due to Perilipin 1 haploinsufficiency (251). In all cases, 
mutated Perilipin 1 failed to sequester to Cgi-58/ABHD5, resulting in 
constitutively active ATGL and uncontrolled lipolysis (251).    
 Cidec 
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 Cidec promotes unilocular LD formation and inhibit lipolysis in adipocytes. 
A patient with a homozygous nonsense mutation in Cidec has been metabolically 
characterized. This mutation resulted in a truncation of the C-terminus of Cidec 
and FPL with insulin-resistant diabetes (252). Strikingly, white adipocytes from 
the patient were characterized by small, multilocular LDs, much like adipocytes 
from Fsp27-deficient animals, and the mutated Cidec failed to localize to LDs 
(220,252).  
Cgi-58/ABHD5 and ATGL 
 Cgi-58 is a LD-localized co-activator protein of the major TG-specific 
lipase ATGL (221). Mutations in Cgi-58 have been characterized and result in 
Chanarin-Dorfman Syndrome (CDS), an autosomal recessive NLSD 
characterized by TG deposition in non-adipose tissue and ichthyosis (253). Eight 
different mutations in Cgi-58 were characterized from nine different families with 
CDS (254). Mutated Cgi-58 was variable and contained insertions, deletions, 
splice and point mutations. Some mutants failed to localized to LDs and interact 
with Perilipin 1 (255), while other mutants were unable to activate ATGL (221).  
 Eight ATGL gene mutations have also been reported and they all resulted 
in premature stop codons (253). Patients with these mutations manifested NSLD 
with severe myopathy (NSLDM) and, although they did not have ichthyosis, they 
presented with muscle weakness and cardiomyopathy (95-97,256,257).  Most 
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ATGL mutants were truncated in the C-terminal patatin domain and many failed 
to localize to LDs or were enzymatically inactive (95,98). 
HSL 
 A mutation in the DG-specific lipase HSL also caused a milder form of 
NLSD characterized by fatty liver, dyslipidemia, and insulin-resistant diabetes 
(258). This was a frameshift mutation that added 86 AA to the C-terminus of the 
HSL, reducing its abundance and decreasing its lipase activity.   
Seipin 
 Seipin has been suggested to function in LD biogenesis at the ER and 
Seipin mutations cause the autosomal recessive CGL Berardinelli-Seip 
congenital lipodystrophy type 2 (BSCL2) (259). This syndrome is characterized 
by an absence of adipose tissue, hypertriglyceridemia, hepatic steatosis, 
cardiomyopathy, T2D, and often intellectual impairment (260). Most 
characterized mutations resulted in severely truncated and non-functional Seipin 
protein (259,261). Further mutational analysis demonstrated that these mutants 
were mislocalized and mutant cells displayed reduced adipogenic and lipogenic 
gene expression, although the exact mechanism whereby Seipin mutation 
causes BSCL2 is still unknown (262).  
 Research has clarified the roles of certain members of the LD proteome in 
the pathology of human disease. Nonetheless, as the LD proteome is highly 
diverse, further characterization is necessary to pinpoint additional proteins that 
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are critical for proper lipid sequestration in humans. Thus, I strove to uncover 
additional uncharacterized candidate LD proteins in the literature. Hypoxia-
inducible gene 2 (Hig2)/Hypoxia-inducible lipid droplet-associated protein 
(Hilpda) presented a promising target.    
Hypoxia-inducible Gene 2 
Overview 
 Hypoxia-Inducible Gene 2 (Hig2/Hilpda) is a little-studied 7kDa, 63 AA 
protein. It is a direct target of Hypoxia-Inducible Factor 1 alpha (Hif1), but not 
Hif2 (263). Hig2 is induced in hypoxic and glucose-deprived conditions (264). 
As such, its expression is upregulated in cancers with dysregulated hypoxia 
signaling, such as renal clear cell carcinoma (RCC), and it was posed as a 
potential RCC biomarker (265). Early studies suggested that the protein was both 
secreted and activated by Wnt signaling (266), but these claims were later 
refuted (263). 
 In addition to its potential role in cancer, Hig2 may also play a role in lipid 
metabolism and LD dynamics. Ectopically expressed Hig2 localized to LDs in 
cancer cell lines and promoted LD deposition in vitro (263). It also localized to 
LDs in human liver histology sections (263). Work published while this thesis was 
in progress demonstrated that Hig2 is also a target of Ppar (267), similar to the 
LD proteins Perilipin 5, Cidea and Fsp27 (195-197,268,269). Additionally, 
microarray experiments from forskolin-treated primary mouse visceral adipocytes 
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demonstrate that its expression is highly induced upon lipolytic stimulation (270). 
Thus, we strove to explore the role of Hig2 as a potential LD protein in two 
metabolically critical tissues, liver and adipose tissue. 
Project Goals 
Proper adipose tissue lipid sequestration is critical for the prevention of 
lipotoxicity, dyslipidemia, and ectopic lipid deposition. Thus, our lab is particularly 
interested in novel regulators of lipid storage in adipocytes. Furthermore, 
elucidating hepatocyte-specific mechanisms that promote liver steatosis could 
provide therapeutic targets to prevent the initial and reversible stage of NAFLD. 
Therefore, experiments in this thesis are aimed at dissecting the role of Hig2 in 
lipid deposition in liver and adipose tissue, determining the downstream 
signaling pathways by which Hig2 alters lipid deposition, and defining how 
the actions of Hig2 in these signaling pathways affect whole body 
metabolism.   
Two main questions are addressed in this thesis: 
1) What is the role of Hig2 in lipid deposition hepatocytes and adipocytes? 
Does it function as a canonical LD protein and promote TG deposition by 
inhibition of lipolysis? 
2) What is the contribution of hepatocyte and adipocyte-specific Hig2 to 
whole body metabolism? Does the expression of Hig2 promote tissue-
specific lipid sequestration? 
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To answer these questions, experiments in this thesis use both in vitro and in 
vivo methods to elucidate the role of Hig2. In primary hepatocytes, I found that 
ectopically expressed Hig2 localized to LDs and promoted TG deposition and LD 
formation. Conversely, I found that Hig2-deficient hepatocytes had reduced TG 
content, LD size, and LD number. Animals with a hepatocyte-specific Hig2 
deficiency demonstrated improved glucose tolerance and reduced liver weight 
and TG content in the chow-fed condition (Chapter 2). Although expression of 
many genes involved in lipid regulation was unchanged in Hig2-deficient 
hepatocytes, lipid flux was significantly altered. I found that Hig2-deficient 
hepatocytes had increased -oxidation, lipolysis, and TG turnover (Chapter 2). 
As LD proteins in adipose tissue are critical for proper lipid storage and Hig2 is 
ubiquitously expressed, I sought to investigate the role of Hig2 in adipocytes. I 
found that Hig2 expression significantly increased with adipogenic differentiation 
in a human adipocyte cell line and was highly expressed in adipocytes in human 
tissue. Additionally, I found that Hig2 localized to LDs in human and mouse 
adipocyte cell lines (Chapter 3). Mice with an adipocyte-specific Hig2 deletion 
had reduced adipose tissue weight and improved glucose tolerance, but 
unchanged lipolysis measurements, excepting increased HSL phosphorylation. I 
found that these differences in fat pad weight, glucose tolerance, and HSL 
phosphorylation were all abrogated at thermoneutrality, a housing condition 
which poses no thermal stress. As thermoneutrality reduces catecholamine 
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levels and thus deactivates BAT, I hypothesized that BAT was the tissue 
responsible for the beneficial phenotypes in the adipocyte-specific Hig2 animals. 
Accordingly, animals with a brown adipocyte-specific deletion of Hig2 
demonstrated improved glucose tolerance, suggesting that brown adipocytes do 
largely mediate the beneficial metabolic effects in adipocyte-deficient Hig2 
animals (Chapter 3). Therefore, Hig2 acts as a LD protein in both hepatocytes 
and adipocytes and promotes lipid deposition and glucose intolerance. Thus, 
Hig2 presents a promising target for the treatment of NAFLD and T2D.  
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CHAPTER II: The Lipid Droplet Protein Hypoxia-inducible Gene 2 
Promotes Hepatic Triglyceride Deposition by Inhibiting 
Lipolysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter is derived from the article with the same name published in the 
Journal of Biological Chemistry: 
DiStefano, M. T., Danai, L. V., Roth Flach, R. J., Chawla, A., Pedersen, D. J., 
Guilherme, A., and Czech, M. P. (2015) J Biol Chem 290, 15175-15184. 
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Summary: 
The liver is a major site of glucose, fatty acid (FA), and triglyceride (TG) 
synthesis and serves as a major regulator of whole body nutrient homeostasis. 
Chronic exposure of humans or rodents to high-calorie diets promotes non-
alcoholic fatty liver disease (NAFLD), characterized by neutral lipid accumulation 
in lipid droplets (LD) of hepatocytes. In this chapter, it is shown that the LD 
protein Hypoxia-inducible gene 2 (Hig2/Hilpda) functions to enhance lipid 
accumulation in hepatocytes by attenuating TG hydrolysis. Hig2 expression 
increased in livers of mice on a high fat diet (HFD) and during fasting, two states 
associated with enhanced hepatic TG content. Hig2 expressed in primary mouse 
hepatocytes localized to LDs and promoted LD TG deposition in the presence of 
oleate. Conversely, tamoxifen-inducible Hig2 deletion reduced both TG content 
and LD size in primary hepatocytes from mice harboring floxed alleles of Hig2 
and a cre/ERT2 transgene controlled by the ubiquitin C promoter. Hepatic TG 
was also decreased by liver-specific deletion of Hig2 in mice with floxed Hig2 
alleles expressing cre controlled by the albumin promoter. Importantly, this 
chapter demonstrates that Hig2-deficient hepatocytes exhibit increased TG 
lipolysis, TG turnover, and fatty acid oxidation compared with controls. 
Interestingly, mice with liver-specific Hig2 deletion also display improved glucose 
tolerance. Taken together, these data indicate that Hig2 plays a major role in 
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promoting lipid sequestration within LDs in mouse hepatocytes through a 
mechanism that impairs TG degradation. 
Introduction: 
The liver is a major site of glucose, TG, and FA synthesis and serves as a 
master regulator of whole body nutrient homeostasis (271). Chronic exposure of 
humans or rodents to high-calorie diets can lead to a disease spectrum known as 
NAFLD (272). This syndrome begins with simple neutral lipid accumulation in 
liver, progresses to liver inflammation, and can culminate in irreversible cirrhosis 
and hepatocellular carcinoma (273). Overabundance of liver lipids has also been 
associated with insulin resistance both in humans and rodents (274), although 
these conditions can also appear independently (130). Thus, understanding the 
molecular pathways that contribute to hepatic lipid accumulation is important in 
addressing therapeutic strategies for NAFLD and in understanding how it relates 
to metabolic disease. 
 In all cells including hepatocytes, neutral lipids are stored in organelles 
termed LDs (275). These LDs are highly dynamic and are regulated by the 
nutritional status of the organism (173). Two main families of LD-associated 
proteins are the PAT family (173), named for its three founding members 
Perilipin, Adipophilin, and Tip47 that have PAT domains, and the CIDE family 
(200). The PAT family has five members (Perilipin 1-5), while the CIDE family 
has three members (Cidea, Cideb, and Cidec/Fsp27). LDs are heterogeneous in 
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their coats and LD proteins generally demonstrate tissue-specific distribution 
patterns (276). In healthy murine liver, Perilipin 2 and Perilipin 3 promote LD 
formation (277), while Cideb promotes VLDL lipidation (209). Although deletion of 
Perilipin 3 has not yet been performed, genetic deletion of Perilipin 2 or Cideb 
ameliorates hepatic steatosis (208,245). However, in the context of diet-induced 
obesity and fatty liver, Fsp27 (Cidec in humans) and Cidea are critical for LD 
formation (200). Both are highly upregulated in murine liver upon diet-induced 
obesity and genetic deletion of either results in clearance of obesity-associated 
hepatic steatosis (200,206,214). Fsp27 is also relevant to human disease, as a 
patient with a homozygous nonsense mutation in CIDEC displays partial 
lipodystrophy, fatty liver, and metabolic syndrome (248,252). As the LD proteome 
may be quite extensive (278), identifying additional members will shed new light 
on the mechanisms for TG deposition and potentially the basis of human 
disease.  
Hig2 was initially identified in a screen for genes induced by oxygen 
deprivation in human cervical cancer cells and encodes a 7 kDa protein with little 
apparent homology to known proteins (264). Its expression is also increased in 
many cancers, particularly RCC and it is a target gene of both Hif1 and PPAR 
(263-265,267,279). Gimm et al. demonstrated that Hig2 localized to LDs and 
promoted TG deposition in cancer cells in vitro (263). These authors also showed 
that Hig2 co-localized with Perilipins 2 and 3, two LD proteins that are essential 
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for neutral lipid deposition in healthy liver. Due to the importance of hepatic lipid 
homeostasis and deposition, the role of Hig2 in these processes was examined.   
 In this chapter, it is demonstrated that Hig2 localizes to LDs in primary 
mouse hepatocytes. Importantly, its deletion in hepatocytes in vivo causes 
depletion of hepatic TG, indicating that it plays a physiological role in regulating 
liver lipid abundance in mice. Furthermore, it is shown that the basis for its ability 
to promote LD formation and TG deposition in liver is through the inhibition of TG 
lipolysis. 
Materials and Methods:  
Animal Studies: All of the studies performed were approved by the Institutional 
Animal Care and Use Committee (IACUC) of the University of Massachusetts 
Medical School. Animals were maintained in a 12 hour light/dark cycle.  Hig2fl/fl 
animals were purchased from Jackson Laboratories (Hilpdatm1.1Nat/J). For 
metabolic studies, the animals were backcrossed onto C57Bl/6J animals for at 
least 6 generations. Genomic DNA was extracted from the obtained mice and 
subjected to PCR for genotyping using Qiagen Fast Cycling PCR Kit (Hig2fl/fl 
primer 5’-CCGGCAGGGCCTCCTCTTGCTCCTG-3’, 5’ 
GTGTGTTGGCTAGCTGACCCCTCGTG-3’). Hig2fl/fl animals were crossed to a 
tamoxifen-inducible ubiquitous cre mouse line (B6.Cg-Tg(UBC-cre/ERT2)1Ejb/J, 
Jackson Laboratories). Hig2fl/fl animals were also crossed to an albumin cre 
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mouse line (C57BL/6-Tg(Alb-cre)21Mgn/J, Jackson). Cre genotyping was 
performed according to the method of Jackson Laboratories.    
At 5-6 weeks of age, male C57Bl/6J, Hig2fl/fl, or Hig2fl/fl albumin cre+ littermates 
animals were placed on a high fat diet (60% fat, D12492i Research Diets) or fed 
chow (Lab Diet 5P76) for 12 or 16 weeks.  
Mice were fasted 16 hours for glucose tolerance tests and 4 hours for insulin 
tolerance tests. Mice were injected IP with 1g/kg of glucose or 1IU/kg of insulin, 
blood was drawn from the tail vein at the indicated times, and blood glucose 
levels were measured with a Breeze-2-glucose meter (Bayer). Mice were 
euthanized by CO2 inhalation followed by bilateral thoracotomy.  
 
Plasma and lipid analysis: Mice were fasted for 3 hours for plasma lipid 
analysis. Blood was taken via cardiac puncture, and EDTA-containing plasma 
was collected. Total serum cholesterol levels (ab65359, Abcam), serum 
triglyceride levels (Triglyceride Determination Kit, Sigma), serum NEFAs (Wako 
Diagnostics), and -hydroxybutyrate (Sigma) were measured using calorimetric 
assays according to the manufacturer’s instructions. Insulin levels were 
measured with an Insulin ELISA Kit (Millipore) according to the manufacturer’s 
instructions.  
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Triglyceride and Cholesterol Extraction: Whole livers were isolated and flash 
frozen in liquid nitrogen. Lipids were extracted from livers or pelleted hepatocytes 
via the Folch method (280). Lipids were dissolved in isopropanol with 1% Triton-
X100. Triglyceride (Triglyceride Determination Kit, Sigma) and cholesteryl ester 
(ab65359, Abcam) levels were measured using calorimetric assays according to 
the manufacturer’s instructions and normalized to liver weight or hepatocyte 
protein content. 
 
Hepatocyte isolation: Male or female 8-10 week old chow-fed animals were 
anesthetized with an IP injection of 1:1 ketamine:xylazine and perfused with 
HBSS supplemented with 0.5M EGTA. Livers were digested with a perfusion of 
50mg/ml collagenase (Sigma, C6885) in HBSS supplemented with 1mM CaCl2, 
physically dissociated, and filtered through a 100m filter. Hepatocytes were 
washed, centrifuged at low speed, filtered through a 70m filter, and plated at a 
density of 1 million cells/ml.  
 
RNA Isolation and RT-qPCR: Total RNA was isolated from cells or tissues 
using TriPure isolation reagent (Roche) according to the manufacturer’s protocol. 
The isolated RNA was DNase treated (DNA-free, Life Technologies), and cDNA 
was synthesized using iScript cDNA synthesis kit (BioRad). RT-qPCR was 
performed on the BioRad CFX96 using iQ SybrGreen supermix, and 36B4 
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served as the reference gene. Primer sequences are as follows: 36B4 (5’- 
TCCAGGCTTTGGGCATCA-3’, 5’-CTTTATCAGCTGCACATCACTCAGA-3’); 
Hig2 (5’-CATGTTGACCCTGCTTTCCAT-3’, 5’- GCTCTCCAGTAAGCCTCCCA-
3’); Tnf (5’-CCCTCACACTCAGATCATCTTCT-3’, 5’-
GCTACGACGTGGGCTACAG-3’); IL6 (5’-TAGTCCTTCCTACCCCAATTTCC-3’, 
5’-TTGGTCCTTAGCCACTCCTTC-3’); IL1 (5’-
GCAACTGTTCCTGAACTCAACT-3’, 5’-ATCTTTTGGGGTCCGTCAACT-3’); 
F4/80 (5’-CCCCAGTGTCCTTACAGAGTG-3’, 5’-GTGCCCAGAGTGGATGTCT-
3’); CD36 (5’-GAACCACTGCTTTCAAAAACTGG-3’, 5’-
TGCTGTTCTTTGCCACGTCA-3’); Cpt1a (5’-GCTGCTTCCCCTCACAAGTTCC-
3’, 5’-GCTTTGGCTGCCTGTGTCAGTATGC-3’); Mttfa (5’-
AGTTCCCACGCTGGTAGTGT-3’, 5’-GCGCACATCTCGACCC-3’); Ppar (5’-
GACTACCCTTTACTGAAATTACC-3’, 5’-GTGGTCTTCCATCACGGAGA-3’); 
Srebp1c (5’-GGAGCCATGGATTGCACA-3’, 5’-GGCCCGGGAAGTCACTGT-3’); 
Srebp2 (5’-GCAGCAACGGGACCATTCT-3’, 5’-
CCCCATGACTAAGTCCTTCAACT-3’); ApoB (5’-
TGGCTCTGATCCCAAATCCCT-3’, 5’-CCGTGCATTCATTGTCGATCTG-3’); 
Atgl (5’-CAGCACATTTATCCCGGTGTAC-3’, 5’-AAATGCCGCCATCCACATAG-
3’); Perilipin 2 (5’-GACCTTGTGTCCTCCGCTTAT-3’, 5’-
CAACCGCAATTTGTGGCTC-3’); Cidea (5’-TGACATTCATGGGATTGCAGAC-3’ 
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5’-GGCCAGTTGTGATGACTAAGAC-3’); Fsp27 (5’-
ATCAGAACAGCGCAAGAAGA-3’, 5’-CAGCTTGTACAGGTCGAAGG-3’) 
 
Immunoblotting: Tissues and cells were lysed in a high-salt, high-SDS buffer 
(2% SDS, 150mM NaCl, 2mM EDTA) with 1x Halt protease and phosphatase 
inhibitors (Thermo Scientific). Lysates were resolved by 15% SDS-PAGE gel run 
in a 1x Tris-Tricine Buffer (National Diagnostics) and transferred to nitrocellulose 
membranes. Membranes were blotted with the following antibodies: -Actin 
(A2228, Sigma), HA-Tag (2367, Cell Signaling Technology). The Hig2 antibody 
was directed against a 15 amino acid peptide (PPKGLPDHPSRGVGV) at the C 
terminus of murine Hig2 (Rockland Immunochemicals).  
 
Cell Culture: Hepatocytes were isolated from male or female 8-10 week old 
Hig2fl/fl Ubc ERT2 Cre+ animals, plated in M199 adherence media (Life 
Technologies, 11150, supplemented with 2% FBS, 10% BSA, 1%Pen/Strep, 
100nM Insulin, and 100nM Dexamethasone) for 3 hours, changed to M199 
maintenance media (M199 supplemented with 1% Pen/Strep, 100nM Insulin, and 
100nM Dexamethasone) and treated with ethanol vehicle or 2.5M (Z)4-
Hydroxytamoxifen (Sigma H7904) dissolved in filtered ethanol (5mg/ml) for 48 
hours before experiments.  
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For imaging experiments, hepatocytes were plated on collagen-coated Millicell 4 
chambered slides (Millipore) and transfected with GFP control, GFP-Hig2, or 
GFP-Hig2 truncated (missing residues 1-28) constructs using 1.5g DNA, 
Optimem and Lipofectamine 2000 (Life Technologies) according to 
manufacturer’s instructions 48 hours prior to experiments. GFP constructs were 
made using two unique restriction sites Not1 and BamH1 in a pShuttle plasmid 
(Clontech, Mountain View, CA).  cDNA of full-length Hig2 or the PCR product of 
truncated Hig2 was inserted in frame at these two restriction sites. Hepatocytes 
were also infected with HA-tagged adenoviruses 48 hours prior to experiments. 
Adenoviruses were made as follows: The cDNA of the transgene of interest was 
first cloned into a pShuttle plasmid (Clontech, Mountain View, CA) and then 
subcloned into a molecular clone of E1-and E3-deleted human adenovirus 
serotype 5. This adenovirus plasmid backbone was modified from pAdX system 
(Clontech, Mountain View, CA) by introducing a green-white selection 
mechanism (281). The recombinant clones of adenovirus vector with the 
transgene of interest were selected through this green-white screening, 
confirmed by restriction enzyme analyses and rescued in 293 cells after 
restriction enzyme linearization and transfection. The recombinant virus is 
expanded and purified by standard CsCl gradient sedimentation followed by 
dialysis for desalting (282). The HA control construct was made by inserting 3HA 
at Not1 and BamH1 sites of the 4124 base pair plasmid pShuttle Adeno vector. 
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3HA Hig2 adenovirus plasmid DNA was made by inserting a full-length gene of 
Hig2 at restriction sites Blp1 (5’) and BamH1 (3’) of 3HA adeno viral plasmid 
DNA. Cells were loaded with the indicated concentration of oleic acid (Sigma) 
dissolved in ethanol and conjugated to 10% fatty acid-free BSA dissolved in 0.1M 
Tris pH 8. For radiation experiments, hepatocytes were plated on collagen-
coated plates in William’s E Medium Adherence Media (Life Technologies 12551, 
supplemented with 2% Fetal Bovine Serum, 10% BSA (Sigma A4503), 1% 
Pen/Strep, 100nM Insulin, and 100nM Dexamethasone). After three hours, media 
was changed to maintenance media (William’s E Medium supplemented with 1% 
Pen/Strep, 100nM Insulin, and 100nM Dexamethasone). 
 
Cell Imaging: Cells were fixed in 10% buffered formalin in PBS for 15 minutes, 
stained with Oil-Red-O, and mounted with Prolong Gold with DAPI (Life 
Technologies). Cells were imaged at room temperature with a Solamere 
Technology Group modified Yokogawa CSU10 Spinning Disk Confocal with a 
Nikon TE-2000E2 inverted microscope at 20x, 60x, and 100x. Images were 
acquired with MetaMorph Software, version 6.1 (Universal Imaging, Downington 
PA). 
Lipid droplet analysis was performed on fixed, Oil-Red-O- and DAPI- stained 
cells with BioPix iQ Imaging Software (BioPix AB, Sweden). At least 90 cells 
were analyzed per condition. 
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Oleate Tracer Studies: Hepatocytes were isolated from male 8-10 week old 
Hig2fl/fl or Hig2fl/fl albumin cre+ animals. 24 hours after isolation, cells were loaded 
with 1Ci/ml [3H] oleic acid mixed with 100M oleic acid conjugated to 0.5% fatty 
acid-free BSA in William’s E Medium. Assays were performed as previously 
described (214,283).  
Oleate Uptake: Cells were loaded with 100M [3H] oleic acid overnight. The 
following day, media was removed, cells were washed, and lysed in 0.5ml of lysis 
buffer (1% Triton-X100 in PBS), and lysates were placed in vials with scintillation 
fluid and counted using a Beckman LS 6500 scintillation counter. Counts were 
normalized to length of incubation time and protein content. 
Total -Oxidation: Cells were loaded with 100M [3H] oleic acid overnight. The 
following day, media was collected, precipitated twice with perchloric acid and 
BSA, spun to pellet insoluble products, and the soluble fraction was removed, 
placed in vials with scintillation fluid, and counted. Counts were normalized to 
length of incubation time and protein content. Empty media was loaded with [3H] 
oleic acid, precipitated, counted, and subtracted as a background reading. 
Triglyceride Turnover: Cells were loaded with 100M [3H] Oleic Acid overnight. 
The following day, cells were washed 2x, and media was replaced with William’s 
E Media with 0.6mM Triacsin C (Sigma). Cells were collected at indicated times, 
washed, and lysed in 0.5ml lysis buffer (1% Triton-X100 in PBS), placed in vials 
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with scintillation fluid, and counted. Counts are normalized to protein content and 
graphed as a percentage of time 0.  
Lipolysis: Cells were loaded with 100M [3H] oleic acid overnight. The following 
day, cells were washed 2x and media was replaced with William’s E Media with 
0.6 mM Triacsin C (Sigma) and 100M Etomoxir (Sigma). Media was collected at 
the indicated times, placed in vials with scintillation fluid, and counted. Counts 
are normalized to protein content.    
 
Statistical Analysis: Data were analyzed in GraphPad Prism 6 (GraphPad 
Software, Inc.). A two-tailed student’s t test with Welch’s Correction was used to 
compare two groups of data. Where indicated, data were analyzed using a two-
way ANOVA with repeated measures or a linear regression model.  P<.05 was 
considered to be significant. The Grubb’s test was used to determine if there 
were statistical outliers and if an outlier was determined, it was removed from the 
statistical analysis. Variance was estimated using standard error of the mean. 
 
Results: 
Hig2 is localized to LDs and its expression is modified by nutritional status. 
To characterize Hig2 as a potential hepatic LD protein, its localization was 
first determined in primary mouse hepatocytes. Primary hepatocytes were 
isolated from C57Bl/6J animals and transfected with either GFP control or GFP-
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tagged Hig2 constructs and incubated with oleic acid to induce LD formation. 
While the GFP control construct displayed a diffuse, cytoplasmic distribution in 
the cells, GFP-Hig2 clearly localized around the perimeter of Oil-Red-O positive 
LDs (Figure 2.1B). Gimm et al. used deletion analysis to determine that the 37 N- 
terminal amino acids of Hig2 are required for LD targeting in cancer cell lines 
(263), which was termed here as the “Putative Lipid Droplet Binding Domain” 
(Figure 2.1A). To confirm that this was also the targeting domain in hepatocytes, 
a Hig2 truncation mutant with a loss of amino acids 1-28 of this putative binding 
domain was created. When the Hig2 truncation mutant was transfected into 
primary hepatocytes, it also localized diffusely, similar to the GFP control, 
demonstrating that Hig2 localizes to LDs in hepatocytes through this putative LD 
binding domain (Figure 2.1B). As Gimm et al. determined by sequence analysis 
that an amphipathic helix is located in this domain (263), it is possible that Hig2 
may interact with the lipid droplet directly via surface interaction (160). 
 Hepatic LD protein expression is highly sensitive to nutritional status. As 
both Fsp27 and Cidea, two bona fide liver LD proteins, are highly upregulated 
upon high fat diet (HFD) feeding in mice (200), Hig2 expression was measured in 
two situations of hepatic steatosis. Fasting, which liberates lipids from adipose 
tissue via lipolysis, causes a temporary increase in liver lipids (128). Indeed, a 
24-hour fast caused a 2-fold increase in Hig2 mRNA expression in C57Bl/6J 
mouse livers (Figure 2.1C). Obesity-induced hepatic steatosis in C57Bl/6J mice 
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also caused a significant 2.7-fold increase in Hig2 mRNA expression in liver 
(Figure 2.1D), consistent with the concept that Hig2 expression is highly 
correlated with liver lipid levels. 
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Figure 2.1 Hig2 is localized to LDs and its expression is modified by 
nutritional status. 
 
 
FIGURE 2.1 Hig2 is localized to LDs and its expression is modified by 
nutritional status. A, amino acid sequence of murine Hig2 with putative lipid 
droplet binding domain residues 1-37 indicated. B, hepatocytes were transfected 
with GFP-tagged constructs (green), loaded with 500M oleic acid for 4 h, fixed, 
and stained with Oil Red O (red) and DAPI (blue). Truncated Hig2-GFP is 
missing residues 1-28. C and D, whole livers were isolated from C57Bl/6J 
animals, RNA was extracted, and qRT-PCR was performed for Hig2 and 
normalized to 36B4. C, animals were fasted for 24 h or fed. Data are represented 
as the mean + S.E. (*, p<0.05, n=6). D, animals were fed ND or HFD for 12 
weeks. (*, p<0.05, n=5-6). Data are represented as the mean + S.E.  
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Ectopic expression of Hig2 promotes hepatocyte lipid deposition. 
LD protein overexpression can also promote lipid deposition (173). For 
example, experimentally enhancing Fsp27 expression promotes TG 
accumulation in a variety of cell types, while Fsp27 deficiency reduces LD 
formation (215,220). Thus, it was tested whether Hig2 expression modifies TG 
accumulation in liver by manipulating Hig2 expression in primary mouse 
hepatocytes. First, primary hepatocytes were isolated from Hig2fl/fl animals and 
infected with either control adenovirus (AV) or an AV expressing HA-tagged 
Hig2. As expected, Hig2-HA AV- infected cells demonstrated increased Hig2-HA 
levels compared with controls as determined by Western blot (Figure 2.2B). The 
cells were incubated with 250M oleic acid for 24 hours to induce LD formation, 
fixed, and then stained with Oil-Red-O to image LDs. Imaging revealed that Hig2-
HA AV- infected hepatocytes had significantly more LDs compared with controls 
(Figure 2.2A). Though there was no significant difference in TG levels in BSA 
vehicle-treated hepatocytes, Hig2-infected cells demonstrated a 1.5-fold increase 
in TG content compared with control cells after oleate loading (Figure 2.2C). 
Taken together, these results demonstrate that high Hig2 expression is sufficient 
to promote lipid deposition in hepatocytes. These results confirmed those of a 
report published while these studies were in progress showing that 
overexpression of Hig2 in liver via adeno-associated virus (AAV) vector injection 
in mice resulted in increased hepatic lipid deposition in vivo (267). 
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Figure 2.2 Ectopic expression of Hig2 promotes hepatocyte lipid 
deposition. 
 
 
FIGURE 2.2 Ectopic expression of Hig2 promotes hepatocyte lipid 
deposition. Hepatocytes were isolated from Hig2fl/fl animals and infected with 
HA (control) or Hig2-HA (Hig2) adenovirus. A and C, hepatocytes were loaded 
with 250M oleic acid for 24 h. A, cells were fixed and stained with Oil red O 
(red) and DAPI (blue). B, representative immunoblots (IB) of Hig2 (light and dark 
exposure), HA-Tag, and -actin. Ctrl, control. C, triglyceride content from control 
and Hig2-HA infected cells. (*, p<0.05, n=6). Data are represented as the mean + 
S.E. 
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Inducible Hig2 deficiency reduces LD triglyceride in hepatocytes. 
Conversely, to determine whether Hig2 expression is necessary for lipid 
deposition in hepatocytes, Hig2 was genetically deleted in primary hepatocytes 
using a tamoxifen-inducible mouse model (Hig2iKO). Hig2fl/fl mice were crossed 
to Ubc ERT2 cre+ mice (Figure 2.3A), hepatocytes were isolated from these 
Hig2iKO animals, plated for 3 hours, and treated with either 2.5M 4-OH-
tamoxifen to induce deletion or ethanol vehicle as a control for 48 hours before 
analysis (Figure 2.3B). Tamoxifen treatment resulted in a 90% reduction in Hig2 
mRNA and protein expression compared with ethanol vehicle- treated controls as 
assessed by qRT-PCR and Western blot, respectively (Figure 2.3C-D). When TG 
was extracted and quantified, it was found that ethanol vehicle-treated cells had 
1.7-fold more TG after BSA treatment and 1.4-fold more TG after oleic acid 
loading compared with tamoxifen-treated cells (Figure 2.3E). These results 
demonstrate that Hig2 deficiency greatly reduced TG deposition in hepatocytes. 
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Figure 2.3 Inducible Hig2 deficiency reduces LD triglyceride in hepatocytes. 
 
 
 
 
 
FIGURE 2.3 Inducible Hig2 deficiency reduces LD triglyceride in 
hepatocytes. A, schematic of Hig2 deletion with tamoxifen-inducible UbcERT2-
cre. B, schematic of experimental design. Hepatocytes were isolated from 
Hig2iKO mice, plated for 3 h, and treated with ethanol vehicle or 2.5M tamoxifen 
in ethanol for 48 h. C, qRT-PCR was performed for Hig2 and normalized to 36B4. 
(**, p<0.01, n=8). D, representative immunoblots (IB) of Hig2 and -actin. Veh, 
vehicle; Tam, tamoxifen. E, triglyceride content from cells treated with 500M 
oleic acid or BSA vehicle for 4h. (*, p<0.05, n=5). 
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Inducible Hig2 deficiency reduces LD size and number in hepatocytes. 
 Cells were fixed and stained with Oil-Red-O, and LDs were 
quantified. Strikingly, tamoxifen-treated hepatocytes had less Oil-Red-O-positive 
LD compared with ethanol vehicle-treated controls (Figure 2.4A). To confirm that 
this was not a side effect of tamoxifen treatment or the Ubc ERT2 cre transgene, 
Ubc ERT2 cre+ hepatocytes on a wild type background were treated with vehicle 
or tamoxifen and no alterations in lipid accumulation were observed (Figure 
2.4D). The ethanol vehicle-treated hepatocytes demonstrated an average of 63 + 
8 LD per cell, while tamoxifen-treated hepatocytes displayed over a 67% 
reduction in LD content and had an average of only 18 + 3 LD per cell (Figure 
2.4B). Furthermore, the LDs in Hig2iKO hepatocytes were approximately 50% 
smaller than ethanol vehicle-treated controls and displayed an average size of 
2.3 + 0.6 m2 compared with 4.3 + 0.6 m2 for ethanol vehicle-treated controls 
(Figure 2.4C). Interestingly, Hig2-deficient hepatocytes had significantly more 
LDs than controls after loading with 500M oleic acid for 24 hours (41 + 6 
compared with 75 + 11); however, these LDs were over 50% smaller than control 
LDs (4.0 + .8 m2  vs. 9.3 + 1.8 m2) (Figure 2.4B,C). This phenomenon is 
similar to the smaller LDs found in Fsp27-deficient adipocytes (220). These 
results demonstrate that Hig2 deficiency greatly reduced LD abundance 
deposition in hepatocytes. Taken together, these experiments in primary 
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hepatocytes suggest Hig2 expression is required for hepatocyte lipid deposition 
and LD growth in vitro.  
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Figure 2.4 Inducible Hig2 deficiency reduces LD size and number in 
hepatocytes. 
 
 
FIGURE 2.4 Inducible Hig2 deficiency reduces LD size and number in 
hepatocytes. A, hepatocytes were treated with BSA vehicle or 500M oleic acid 
for 24 h, fixed, and stained with Oil-red-O (red) and DAPI (blue). B and C, 
hepatocytes were treated with 500M oleic acid or BSA vehicle for 24 h. B, the 
number of lipid droplets per cell. C, total lipid droplet area per cell. (*, p<0.05, **, 
p<0.01, n=5-6). Data are represented as the mean + S.E. D, C57Bl/6J Ubc ERT2 
cre+ hepatocytes were isolated  and treated as in Figure 2.3, treated with 500M 
oleic acid for 24h, fixed, and stained with Oil-red-O (red) and DAPI (blue). 
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Liver-specific Hig2-deficient mice display hepatocyte-specific Hig2 deletion. 
 Excess accumulation of liver lipids is often associated with insulin 
resistance in obese mice and humans (274). Therefore, mice with liver-specific 
deletion of Hig2 were generated to address whether Hig2 deficiency could 
reduce hepatic steatosis and preserve glucose tolerance in a model of diet-
induced obesity. The Hig2fl/fl mouse was crossed with mice expressing albumin 
cre to generate a mouse with liver-specific Hig2 deletion (Hig2LKO, Figure 2.5A). 
Hig2LKO mice demonstrated a significant, 89% reduction of Hig2 mRNA 
specifically in hepatocytes compared with fl/fl controls (Figure 2.5B) and a 
concomitant reduction in Hig2 protein levels as determined by Western blot 
(Figure 2.5C). Other tissues such as white adipose tissue (WAT), spleen, and 
kidney did not show significant reductions in Hig2 mRNA (Figure 2.5D), 
demonstrating that the deletion was specific for hepatocytes. 
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Figure 2.5 Liver-specific Hig2-deficient mice display hepatocyte-specific 
Hig2 deletion. 
 
 
FIGURE 2.5 Liver-specific Hig2-deficient mice display hepatocyte-specific 
Hig2 deletion. A, schematic of albumin-cre-mediated Hig2 deletion. B and C, 
hepatocytes were isolated from fl/fl and Hig2LKO mice. B, qRT-PCR was 
performed for Hig2 and normalized to 36B4. (#, p<.005, n=5). Data are 
represented as the mean + S.E. C, representative immunoblots (IB) of Hig2 and 
-actin. D, white adipose tissue (WAT), kidney, and spleen were isolated from fl/fl 
and Hig2LKO mice. qRT-PCR was performed for Hig2 and normalized to 36B4. 
(n=8-9).Data are represented as the mean + S.E. 
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Liver-specific Hig2-deficient mice display decreased liver triglyceride in normal 
diet conditions and improved glucose tolerance. 
Fl/fl and Hig2LKO animals were placed on HFD or normal diet (ND) for 16 
weeks and their body weight was measured weekly. Although there was no 
significant difference in the body weights of the Hig2LKO animals versus the fl/fl 
controls (Figure 2.6A), the Hig2LKO animals demonstrated significantly improved 
glucose tolerance as measured by a glucose tolerance test (GTT) in both the ND 
group and at early time points following glucose injection in the HFD-fed group 
(Figure 2.6B). However, no significant difference between genotypes was 
observed in an insulin tolerance test (ITT, Figure 2.6C).  
Fasting circulating insulin levels, serum TGs, serum cholesterol, serum 
non-esterified fatty acids (NEFA), -hydroxybutyrate and liver cholesterol were 
measured, but all were unchanged among the groups in both ND and HFD-fed 
conditions (Table 2.1). Because Hig2 deletion reduces TG content in vitro, the 
livers of the Hig2LKO animals fed ND or HFD for 16 weeks were examined. The 
gross liver weights were not significantly different in either diet condition, but in 
the ND condition, the Hig2LKO animals had lighter livers than the fl/fl controls 
(1.14 + .04 vs. 1.23 + .03g, p=.08) (Figure 2.6D). Though differences in H&E 
stained histology sections from fl/fl and Hig2LKO animals were unremarkable 
(Figure 2.6F), ND-fed Hig2LKO animals had 30% less liver TGs than fl/fl controls 
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(p=.08); however, this difference was abrogated in HFD-fed animals (Figure 
2.6E).  
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Figure 2.6 Liver-specific Hig2-deficient mice display decreased liver 
triglyceride in normal diet conditions and improved glucose tolerance. 
 
 
 
FIGURE 2.6 Liver-specific Hig2-deficient mice display decreased liver 
triglyceride in normal diet conditions and improved glucose tolerance. A-F, 
fl/fl or Hig2LKO animals were fed ND or HFD for 16 weeks. A, body weight 
curves. (n=10-13). B, glucose tolerance test. (+, p=0.08, *, p<0.05, **, p<0.01; $, 
p<0.05, two-way analysis of variance, n=7-11). C, insulin tolerance test. (n=9-17). 
Data are represented as the mean + S.E. D, liver weights. (+, p=0.08, n=8-11). 
Data are represented as individual values + S.E. E, lipids were extracted from 
livers, and triglyceride content was assessed. (+, p=0.08, n=8-11). Data are 
represented as individual values + S.E. F, livers were sectioned and stained with 
H&E. 
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Table 2.1 
Liver cholesterol and serum metabolites were assessed from fl/fl or Hig2LKO 
animals fed ND or HFD for 16 weeks. (n=5-13). Data are the mean + S.E. 
BD, below detection; NEFA, non-esterified fatty acids. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parameters
Hig2 fl/fl Hig2LKO Hig2 fl/fl Hig2LKO
Insulin (ng/ml) BD BD 2.831 + 0.477 2.640 + 0.268
Serum triglycerides (mg/dL) 64.283 + 4.302 51.456 + 5.113 107.384 + 6.634 102.954 + 10.707
Serum cholesterol (mg/dL) 64.401 + 5.782 70.218 + 5.929 127.834 + 6.993 137.622 + 6.255
Liver cholesterol (g/mg) 1.745 + 0.106 1.717 + 0.071 1.804 + 0.226 2.181 + 0.082
NEFA (mmol/liter) 0.416 + 0.028 0.348 + 0.038 0.536 + 0.068 0.476 + 0.058
-Hydroxybutyrate (mmol/liter) 0.469 + 0.042 0.569 + 0.078 0.373 + 0.038 0.274 + 0.017
Normal Diet 16wks HFD
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Gene expression in inflammatory, lipid, and energy metabolism pathways is 
unchanged in liver-specific Hig2-deficient mice. 
To assess liver inflammation, RNA was isolated from mice fed HFD for 16 
weeks and qRT-PCR was performed to assess the expression of genes involved 
in inflammatory pathways. No changes in gene expression were observed in 
Hig2LKO mouse livers compared with fl/fl controls for TNF, IL6, IL1, and the 
macrophage marker F4/80 (Figure 2.7A). 
It was critical to examine potential mechanisms by which Hig2 controls TG 
accumulation in hepatocytes. Hepatic TG accumulation is controlled by FA 
uptake and hepatic lipogenesis versus hepatic lipolysis (TG turnover) (11). First, 
qRT-PCR on RNA isolated from livers isolated from fl/fl and Hig2LKO mice on 
ND was performed and the expression was assessed of several genes that are 
critically involved in the aforementioned pathways. However, no changes in gene 
expression were observed in Hig2LKO mouse livers compared with fl/fl controls 
for CD36 (FA uptake), Cpt1a, Mttfa (mitochondrial oxidation), Ppar, Fasn, 
Srebp1c (lipogenesis), Srebp2 (cholesterol synthesis), ApoB (lipid export), or Atgl 
(lipolysis) (Figure 2.7B). Hig2 deficiency could potentially reduce the expression 
of other LD proteins in liver to reduce the lipid content, thus the expression of 
Perilipin 2, Cidea, and Fsp27 by qRT-PCR was measured and the expression of 
these genes was also unchanged in Hig2LKO mouse livers compared with fl/fl 
livers (Figure 2.7C). 
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Figure 2.7 Gene expression in inflammatory, lipid, and energy metabolism 
pathways is unchanged in liver-specific Hig2-deficient mice.  
 
 
 
FIGURE 2.7 Gene expression in inflammatory, lipid, and energy metabolism 
pathways is unchanged in liver-specific Hig2-deficient mice. A-C, whole 
livers were isolated from fl/fl or Hig2LKO animals, RNA was extracted, and qRT-
PCR was performed for the indicated genes and normalized to 36B4. A, animals 
were fed HFD for 16 weeks. Data are represented as the mean + S.E. (n=4-9). B, 
C animals were fed ND for 16 weeks. (n=3-4). Data are represented as the mean 
+ S.E.  
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Hig2 deficiency increases hepatocyte lipolysis, -oxidation, and triglyceride 
turnover. 
 Because there were no transcriptional changes in the targets examined, it 
was hypothesized that Hig2 was promoting hepatic lipid deposition in a post-
transcriptional manner. Thus, lipid flux in Hig2LKO hepatocytes was assessed to 
determine whether they demonstrated a difference in lipid handling. Hepatocytes 
were isolated from ND-fed fl/fl and Hig2LKO hepatocytes, the cells were 
incubated with [3H] oleic acid and then the total amount of radiation was 
measured in Hig2LKO and fl/fl controls after overnight [3H] oleic acid loading. As 
expected, the Hig2LKO hepatocytes displayed a 45% reduction in lipid uptake 
compared with controls (p=.07; Figure 2.8A), confirming results obtained in 
Figure 2.3 with the Hig2iKO hepatocytes.  
Genetic deletion of LD proteins such as Fsp27, Perilipin1, and Cidea in 
mice, has demonstrated a role for LD proteins in TG turnover and -oxidation 
(177,203,220,284). Hepatic TG turnover has been experimentally determined to 
be on the timescale of 10-30 hours in vivo (285). Thus, parameters were 
assessed by loading the ND-fed Hig2LKO or fl/fl hepatocytes with [3H] oleic acid 
overnight and then TG turnover, lipolysis, and -oxidation were measured. 
Strikingly, despite the absence of changes in gene expression, Hig2LKO 
hepatocytes had significantly increased TG turnover compared with fl/fl controls 
as determined by linear regression analysis (Figure 2.8C). Hig2LKO hepatocytes 
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also exhibited double the amount of lipolysis at two hours as compared with 
controls (Figure 2.8D). Similar to Fsp27-deficient animals, Hig2LKO hepatocytes 
also displayed 3.3-fold higher degree of FA oxidation compared with control fl/fl 
hepatocytes as detected by accumulation of soluble [3H] oleic acid oxidation 
products  (Figure 2.8B). Taken together, these results suggest that Hig2 
promotes lipid deposition in a healthy liver, at least in part, by localizing to LDs in 
hepatocytes and inhibiting TG lipolysis. 
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Figure 2.8 Hig2 deficiency increases hepatocyte lipolysis, -oxidation, and 
triglyceride turnover. 
 
 
FIGURE 2.8 Hig2 deficiency increases hepatocyte lipolysis, -oxidation, 
and triglyceride turnover. A-D, hepatocytes were isolated from fl/fl or Hig2LKO 
animals, plated, and loaded with 100M [3H]oleic acid overnight. A, oleate 
uptake. (+, p=0.07, n=8). B, total -oxidation. (*, p<0.05, n=6). C, triglyceride 
turnover. (*, p<0.05 via linear regression analysis of the slope, n=8-10). D, 
lipolysis. (*, p<0.05, n=3) Data are represented as the mean + S.E. 
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Discussion: 
The findings presented in this chapter define Hig2 as a physiologically 
important LD-associated protein that functions to promote TG accumulation in 
liver in vivo. It is demonstrated that GFP-tagged Hig2 localizes specifically to 
hepatocyte LDs in a manner that was dependent on its putative lipid binding 
domain (Figure 2.1). While ectopic expression of Hig2 promoted LD abundance 
and TG deposition (Figure 2.2), Hig2 deletion in hepatocytes in vitro reduced TG 
accumulation (Figure 2.3) and LD number (Figure 2.4). Liver-specific Hig2 
deletion (Figure 2.5) reduced hepatic TGs in ND-fed mice and improved glucose 
tolerance in both ND and HFD-fed conditions (Figure 2.6). Hepatocytes isolated 
from these animals, despite showing no discernable gene expression changes 
(Figure 2.7), showed increased TG turnover and FA oxidation, suggesting that 
Hig2 promotes TG deposition by inhibiting lipolysis (Figure 2.8). Indeed, direct 
measurement of TG hydrolysis in hepatocytes deficient in Hig2 revealed 
increased lipolytic rates over controls, analogous to what has been reported for 
other LD proteins, such as Fsp27 (214).  
 As the data in Figure 2.5 indicate, Hig2 may not be nearly as crucial for 
hepatic lipid deposition in HFD-fed liver as it is in the ND-fed condition. No 
decrease was found in total liver TG in the Hig2LKO mice compared with fl/fl 
controls when both groups of mice were on a HFD. This contrasts with a 
decrease in liver TG observed in these Hig2LKO mice on ND (Figure 2.5). One 
87 
 
 
likely possibility to explain this result is other proteins that are redundant in 
function to Hig2. 
Many LD proteins in the PAT family and the CIDE family alter lipid 
deposition by inhibiting lipolysis (173,180,200). Some of these are upregulated 
under HFD conditions and could replace Hig2 action on lipolysis. For example, 
the expression of the LD protein Fsp27 is highly upregulated by the fatty liver 
conditions we have examined here (286). Fsp27 inhibits lipolysis in adipocytes 
(215), similar to the present findings on Hig2 and hepatocytes. Taken together, it 
seems likely that compensation by other upregulated LD proteins explains the 
failure of Hig2 depletion to lower liver TG under HFD conditions.  
 These findings complement the recent findings of Mattijssen et al. (267) 
which were published while these studies were in progress. The authors 
demonstrated that overexpression of Hig2 in mouse livers driven by AAV results 
in hepatic steatosis, similar to our results using AV as an expression vector for 
Hig2 (Figure 2.2). Consistent with their findings, increased lipid product export 
was also observed in hepatocytes from Hig2LKO mice compared with controls 
(Figure 2.8), but this export consists almost entirely of FA oxidation products 
rather than lipoproteins. It has been shown that increases in lipolysis can shunt 
FAs to the mitochondria, leading to increases in -oxidation (287). It was also 
observed that Hig2LKO hepatocytes had increased lipolysis and TG turnover, 
which is phenotypically similar to what is observed after loss of LD proteins and 
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further suggests that Hig2 acts similarly to other proteins in this class. Thus, the 
increased -oxidation products observed in Hig2-deficient hepatocytes most 
likely reflect the higher levels of lipolysis and free FA availability for oxidation 
observed in the Hig2-deficient hepatocytes.  
The increased lipolysis in Hig2LKO hepatocytes does not appear to be the 
result of altered expression of Atgl (Figure 2.7B), the rate-limiting TG lipase in 
adipose tissue. However, Atgl activity is inhibited by G0/G1 Switch Protein 2 
(G0S2) (222,288). Hig2 could function similarly to negatively regulate lipolysis by 
interacting with and inhibiting Atgl or other lipases in liver. The lipolysis pathway 
in liver is not well studied, but liver-specific Atgl depletion in mice increases liver 
TG, while overexpression reduces liver TGs and increases -oxidation 
independent of changes in hepatic gene expression or serum TGs, much like we 
observe in the Hig2LKO mouse (289-291). Sequence alignments of Hig2 and 
G0S2 show 13.5% sequence identity, mostly located in the area where G0S2 is 
known to bind and inhibit Atgl (Figure 2.9) (222,292,293). Another target of Hig2 
regulation could be Adiponutrin, a lipase from the patatin-like phospholipase 
domain containing (PNPLA) family that contains the most sequence similarity to 
Atgl (287). If Hig2 physically interacts with a lipase, it could either inhibit its 
activity or restrict its access to LDs. The exact mechanism by which Hig2 inhibits 
lipolysis will be assessed in future studies. 
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A remarkable finding in this study was the significant improvement in 
glucose tolerance observed in liver-specific Hig2 deficiency, even under HFD 
conditions in which liver TG was unchanged (Figure 2.6). Although in obese 
animals and humans liver TG accumulation generally correlates with insulin 
resistance, many experimental models show dissociation of liver lipid 
accumulation from glucose tolerance, and the precise mechanistic connections 
between liver fat and metabolism and insulin sensitivity are far from clear (294). 
The mechanism by which Hig2 improves glucose tolerance in HFD animals, 
primarily in early time points following glucose injection is also unclear at this 
point. Hig2LKO animals trend toward enhanced insulin sensitivity in an ITT (Fig. 
2.6), although the differences did not reach statistical significance, and the basis 
of improved glucose clearance in these animals is under further investigation. 
Although this work on Hig2 has been performed in murine cells and 
tissues, mutations in other LD proteins such as Fsp27 and Perilipin 1 are 
associated with human disease (251,252). It will therefore be of interest to 
investigate whether Hig2 plays an important role in human biology. Tissue 
expression analysis of Hig2 shows that it is ubiquitously expressed (Figure 2.10). 
This expression pattern parallels that of Perilipin 2, which can be found coating 
LDs in most tissues. This raises the question of whether Hig2 is required for lipid 
deposition in other tissues, particularly metabolically active tissues such as 
adipose tissue and muscle or for macrophage foam cell formation. The full range 
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of Hig2 functions in diverse cell types in human biology is a key question for 
future research. 
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Figure 2.9 Hig2 and G0S2 share sequence homology. 
 
 
FIGURE 2.9 Hig2 and G0S2 share sequence homology. Protein sequences for 
mouse G0S2 and Hig2 were aligned, and sequence identity was calculated using 
the uniProt KB database with the default parameters of the program Clustal 
Omega (292,293).  Amino acid color coding is as follows: red=identical, 
blue=very similar, green=similar. Residues 27-42 of G0S2 are sufficient for ATGL 
binding and are highlighted in yellow. 
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CHAPTER III: Adipocyte-specific Hig2 promotes fat deposition and diet- 
induced glucose intolerance 
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Summary: 
 Adipose tissue is a dynamic organ with inputs into whole body 
metabolism. Proper lipid storage in adipocyte-specific lipid droplets (LDs) is 
critical for metabolic health; one hypothesis suggests that in chronic states of 
over nutrition, adipocytes can no longer buffer the influx of calories, resulting in 
dyslipidemia, which is often associated with metabolic disease. In this chapter, it 
is shown that the LD protein Hypoxia-inducible Gene 2 (Hig2/Hilpda) functions to 
enhance lipid accumulation in adipose tissue. Hig2 expression increased in 
epididymal white adipose tissue (eWAT) of obese mice and differentiating human 
SGBS adipocytes, two states associated with increasing adipocyte TG content. 
Hig2 localized to LDs in mature human SGBS and 3T3-L1 adipocytes. eWAT 
weight and brown adipose tissue (BAT) lipid content were decreased by 
adipocyte-specific deletion of Hig2 in mice with floxed Hig2 alleles expressing cre 
controlled by the adiponectin promoter. Ex vivo lipolysis measurements and 
circulating NEFAs were unchanged in Hig2-deficient animals, suggesting that 
adipocyte-specific Hig2 deficiency may not reduce eWAT weight by increasing 
lipolysis. Interestingly, HFD-fed mice with adipocyte-specific Hig2 deletion also 
displayed improved glucose tolerance. These improvements were abrogated by 
thermoneutrality (30°C), a temperature with no thermal stress and little BAT 
activation, suggesting that active BAT may play a role. Consistent with this idea, 
brown adipocyte-specific deletion of Hig2 in mice with floxed Hig2 alleles 
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expressing cre controlled by the ucp1 promoter also resulted in improved glucose 
tolerance in obesity. Taken together, these data indicate that Hig2 plays a role in 
promoting lipid sequestration within LDs in mouse adipocytes and in promoting 
obesity-induced glucose intolerance. 
Introduction: 
 Once considered an inert storage organ, adipose tissue is a dynamic 
tissue with inputs into whole body metabolism (122). Adipose tissue contains fat 
cells, termed adipocytes, and preadipocytes, immune cells, and endothelial cells 
(295). When digested and separated from the adipocytes, these cells are 
collectively known as the SVF (31). Adipose tissue stores the majority of caloric 
energy in the form of neutral lipids in organelles termed LDs in adipocytes (296). 
LDs are highly dynamic organelles and are regulated by tissue-specific proteins 
embedded in or associated with the droplet termed LD proteins. These proteins 
can regulate the size of the LD by inhibiting or facilitating lipolysis, the breakdown 
of TGs into glycerol and FFAs (297). LD proteins are relevant to human disease, 
as humans with mutations in these proteins manifest lipodystrophy, fatty liver, 
and metabolic syndrome (142). 
 Two main families of LD-associated proteins are the PAT family (173), 
named for its three founding members Perilipin, Adipophilin, and Tip47 that have 
PAT domains, and the CIDE family (200). The PAT family has five members 
(Perilipin 1-5), while the CIDE family has three members (Cidea, Cideb, and 
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Cidec/Fsp27). LDs are heterogeneous in their coats and LD proteins generally 
demonstrate tissue-specific distribution patterns (276). Perilipins 1, 2, 3, and 4, 
Cidea, and Fsp27 are expressed in adipose tissue and localize to LDs in 
adipocytes (Table 1.1). In vitro and in vivo studies suggest that Perilipin 1 and 
Fsp27 are two LD proteins that are critical for lipid storage in adipocytes 
(175,177,180,215,220); these experiments were confirmed by the discovery of 
lipodystrophic humans with Perilipin 1 and Fsp27 mutations (252,298).   
 Proper lipid storage in WAT is critical for metabolic health (295). In a lean 
individual, calories are stored as lipid in adipocytes. One hypothesis suggests 
that in chronic states of over nutrition, adipocytes can no longer buffer the influx 
of calories, resulting in dyslipidemia and ectopic fat deposition in other organs, 
such as liver and muscle, which can lead to insulin resistance, cardiovascular 
disease, inflammation, and cancer (136). Increasing the storage capacity of the 
adipose tissue poses a unique solution to this problem. Thus, further 
investigating the LD proteome for key players in lipid storage could be beneficial 
for human health.  
 Brown adipose tissue (BAT) generates heat through nonshivering 
thermogenesis, an uncoupling of the proton gradient of the electron transport 
chain mediated by UCP1. This differs from shivering thermogenesis, a temporary 
involuntary muscle movement that generates heat (299). Thus, brown adipocytes 
are characterized by high mitochondrial number, high UCP1 expression, and 
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small, numerous (multilocular) LDs (295). Until recently, BAT was thought to be 
present solely for warmth in human infants and hibernating mammals, but 2FDG-
PET scans have revealed that adult humans retain some functional BAT (50).
 As BAT metabolism is energetically expensive, human BAT activation 
presents a unique anti-obesity therapeutic potential. BAT thermogenesis can be 
activated by many means, but one of the most prominent stimuli is increased 
beta-adrenergic activation in response to cold temperatures (47). For example, 
when rodents are housed at room temperature (23°C), a mild cold stress, their 
metabolic rate can increase up to 50% due to BAT energy consumption (60). As 
housing mice at room temperature (23°C) poses such a thermal stress, it can be 
informative to subject mouse models to thermoneutrality, the temperature at 
which they are not subject to any external cold stress, (30°C for mice) to 
eliminate the contribution of nonshivering thermogenesis to whole body 
metabolism (300).  
   Hypoxia-inducible gene 2 (Hig2) is a little-studied 63 amino acid 
protein that was found in microarray analyses to be highly expressed in the 
adipocyte fraction of adipose tissue samples collected from bariatric surgery 
patients (Figure 3.1B). As Hig2 is ubiquitously expressed, promotes lipid 
deposition, and was highly expressed in adipocytes in human patients, its role in 
adipose tissue was examined. 
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 In this chapter, it is demonstrated that Hig2 localizes to LDs in adipocytes. 
Its expression is increased with both adipogenic differentiation and fat deposition. 
Mice harboring an adipocyte-specific deletion of Hig2 demonstrate reduced 
epididymal fat pad weight and improved glucose tolerance on HFD. These 
effects are abrogated by thermoneutral housing, suggesting that BAT may play a 
role in the improvements. This is supported by the fact that mice harboring a 
brown adipocyte-specific deletion of Hig2 also display improved glucose 
tolerance. Interestingly, ex vivo glycerol release, serum NEFAs and 
phosphorylation of PKA substrates are unchanged in adipocyte-specific Hig2-
deficient animals compared with fl/fl controls, suggesting that Hig2 may not inhibit 
lipolysis to promote lipid deposition in adipocytes. Taken together, these results 
suggest that adipocyte-specific Hig2 promotes lipid deposition and glucose 
intolerance, which may be entirely due to its expression in brown adipocytes.  
Materials and Methods:  
Animal Studies: All of the studies performed were approved by the Institutional 
Animal Care and Use Committee (IACUC) of the University of Massachusetts 
Medical School. Animals were maintained in a 12 hour light/dark cycle.  Hig2fl/fl 
animals were purchased from Jackson Laboratories (Hilpdatm1.1Nat/J). For 
metabolic studies, the animals were backcrossed onto C57Bl/6J animals for at 
least 6 generations. Genomic DNA was extracted from the obtained mice and 
subjected to PCR for genotyping using Qiagen Fast Cycling PCR Kit (Hig2fl/fl 
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primer 5’-CCGGCAGGGCCTCCTCTTGCTCCTG-3’, 5’ 
GTGTGTTGGCTAGCTGACCCCTCGTG-3’). Hig2fl/fl animals were crossed to an 
adiponectin cre mouse line (B6;FVB-Tg(Adipoq-cre)1Evdr/J, Jackson 
Laboratories). Hig2fl/fl animals were also crossed to a ucp1 cre mouse line 
(B6.FVB-Tg(Ucp1-cre)1Evdr/J, Jackson Laboratories). Cre genotyping was 
performed according to the method of Jackson Laboratories.    
At 4-6 weeks of age, male C57Bl/6J, Hig2fl/fl, Hig2fl/fl adiponectin cre+, or Hig2fl/fl 
ucp1 cre+ littermates animals were placed on a high fat diet (60% fat, D12492i or 
45% fat, D12451 (Fig 3.1 only), Research Diets) or fed chow (Lab Diet 5P76) for 
8,12,16 or 20 weeks. Animals were switched to thermoneutral housing (30°C, 12 
hour light/dark cycle) for 4 weeks and retained on the same diet they were 
previously fed. 
Mice were fasted 16 hours for glucose tolerance tests and 4 hours for insulin 
tolerance tests. Mice were injected IP with 1g/kg of glucose or 1IU/kg of insulin, 
blood was drawn from the tail vein at the indicated times, and blood glucose 
levels were measured with a Breeze-2-glucose meter (Bayer). Mice were 
euthanized by CO2 inhalation followed by bilateral thoracotomy.  
The metabolic cage studies were performed at the UMass Mouse Metabolic 
Phenotyping Center. Mice were fed HFD for 16 weeks and the metabolic cages 
were used to measure food intake, RER, VO2 consumption, CO2 production, 
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energy expenditure and physical activity over a 3-day period, and an average for 
each parameter was calculated (TSE Systems). 
 
Ex Vivo Lipolysis: Mice were fasted for 16 hours and euthanized by CO2 
inhalation followed by bilateral thoracotomy. Epididymal adipose tissue was 
removed and cut into 80-100mg pieces, placed in 0.5ml Krebs-Ringer-Hepes 
Buffer pH 7.4, supplemented with 2.5% fatty acid-free BSA and 1mM sodium 
pyruvate. Samples were incubated in a 37°C shaking water bath with or without 
10M isoproterenol (Sigma, I5627) for 2 hours and glycerol release into KRH 
was measured using a calorimetric assay (Sigma) according to the 
manufacturer’s instructions and normalized to the fat pad weight. 
 
Adipose tissue fractionation: Whole fat pads were isolated, minced, and 
placed in 5 ml Hanks Balanced Salt Solution (ThermoFisher, 14170120), pH 7.4, 
supplemented with 5% fatty acid-free BSA and 1mg/ml collagenase. Samples 
were incubated in a 37°C shaking water bath for 45 minutes, and the digestion 
reaction was terminated with 5 ml of HBSS and BSA. Tissue was filtered through 
a 200M filter, spun at 200 g for 5 minutes, and adipocyte and stromal vascular 
fractions (SVF) were separated. Both were washed with HBSS 2x and then 
placed in TriPure for RNA isolation. 
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Plasma and lipid analysis: Mice were fasted for 16 hours for plasma lipid 
analysis. Blood was taken via cardiac puncture, and EDTA-containing plasma 
was collected. Total serum cholesterol levels (ab65359 Abcam), serum 
triglyceride levels (Triglyceride Determination Kit, Sigma), serum NEFAs (Wako 
Diagnostics), and serum Glycerol (Free Glycerol Determination Kit, Sigma) were 
measured using calorimetric assays according to the manufacturer’s instructions. 
Insulin and adiponectin levels (Millipore) were measured by ELISA according to 
manufacturer’s instructions.  
 
Triglyceride and Cholesterol Extraction: Whole livers were isolated and flash 
frozen in liquid nitrogen. Lipids were extracted from livers via the Folch method 
(280). Lipids were dissolved in isopropanol with 1% Triton-X100. Triglyceride 
(Triglyceride Determination Kit, Sigma) and cholesteryl ester (ab65359 Abcam) 
levels were measured using calorimetric assays according to the manufacturer’s 
instructions and normalized to liver weight. 
 
 Human samples: Human adipose tissue samples were collected from morbidly 
 obese patients who underwent gastric bypass surgery between 2005 and  2009 
 at the  University of Massachusetts Medical School (301). Samples used for 
 microarray analysis were from BMI-matched female patients, whereas qRT-PCR 
 validations were performed in samples from both males and females. Adipose 
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 tissue samples were obtained from lower abdominal wall (for subcutaneous) and 
 omentum (for visceral) during the surgery. Informed consent was given by the 
 patients and the study was approved by University of Massachusetts Medical 
 School Institutional Review Board. 
RNA Isolation and RT-qPCR: Total RNA was isolated from cells or tissues 
using TriPure isolation reagent (Roche) according to the manufacturer’s protocol. 
The isolated RNA was DNase treated (DNA-free, Life Technologies), and cDNA 
was synthesized using iScript cDNA synthesis kit (BioRad). RT-qPCR was 
performed on the BioRad CFX96 using iQ SybrGreen supermix and 36B4 served 
as the reference gene. Primer sequences are as follows: 36B4 (5’- 
TCCAGGCTTTGGGCATCA-3’, 5’-CTTTATCAGCTGCACATCACTCAGA-3’); 
Hig2 (5’-CATGTTGACCCTGCTTTCCAT-3’, 5’- GCTCTCCAGTAAGCCTCCCA-
3’); Atgl (5’-CAGCACATTTATCCCGGTGTAC-3’, 5’-
AAATGCCGCCATCCACATAG-3’); Hsl (5’-GATTTACGCACGATGACACAGT-3’, 
5’-GCCATATTGTCTTCTGCGAGTG-3’); Cgi-58 (5’-GGTTAAGTCTAGTGCAGC-
3’, 5’- AAGCTGTCTCACCACTTG-3’, 5’-AAGCTGTCTCACCACTTG-3’); G0S2 
(5’- GTGAAGCTATACGTGCTGGG-3’, 5’-CCGTCTCAACTAGGCCGAG-3’); 
Perilipin1 (5’- CTGTGTGCAATGCCTATGAGA-3’, 5’- 
CTGGAGGGTATTGAAGAGCCG-3’); Fsp27 (5’-ATCAGAACAGCGCAAGAAGA-
3’, 5’-CAGCTTGTACAGGTCGAAGG-3’); Ucp1 (5’-
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ACTGCCACACCTCCAGTCATT-3’, 5’-CTTTGCCTCACTCAGGATTGG-3’); 
Prdm16 (5’-CAGCACGGTGAAGCCATTC-3’, 5’-GCGTGCATCCGCTTGTG-3’) 
Human Primers: RPLP0 (5’-CAGATTGGCTACCCAACTGTT-3’, 5’-
GGGAAGGTGTAATCCGTCTCC-3’); HIG2 (5’-
AAGCATGTGTTGAACCTCTACC-3’, 5’-GATGGAGAGTAGGGTCAGTACC-3’) 
 
Immunoblotting: Tissues and cells were lysed in a high-salt, Tris-HCl buffer 
(50mM Tris, pH 8, 150mM NaCl, 1mM EDTA, 1% Triton X-100) with 1x Halt 
protease and phosphatase inhibitors (Thermo Scientific). Lysates were resolved 
by SDS-PAGE gel and transferred to nitrocellulose membranes. Membranes 
were blotted with the following antibodies: -Tubulin (T5168, Sigma), -Actin 
(A5136, Sigma), HSL (4107, Cell Signaling), pHSL(ser563) (4139, Cell 
Signaling), ATGL (2138, Cell Signaling).  
 
Cell Culture: 3T3-L1 fibroblasts were grown and differentiated into adipocytes as 
previously described (302). Briefly, 3T3-L1 fibroblasts were grown to confluence 
in complete medium (high glucose (25mM) DMEM containing 10% fetal bovine 
serum, 50units/ml penicillin, and 50μg/ml of streptomycin). Two days after 
confluence, differentiation medium (0.25μM dexamethasone, 0.5mM 1-methyl-3-
isobutylxanthine, and 10−7M insulin) was added. Cells were considered fully 
mature 7 days post-differentiation.  
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Simpson Golabi Behmel Syndrome (SGBS) cells were obtained from Dr. Martin 
Wabitsch’s laboratory. SGBS fibroblasts were grown and differentiated into 
adipocytes as previously described with modifications (303). Briefly, SGBS 
fibroblasts were grown to confluence in DMEM/F12 containing 10% fetal bovine 
serum, 33M biotin, 17M pantothenic acid, 50units/ml penicillin, and 50g/ml 
streptomycin. Two days after confluence, serum-free differentiation medium 
(25nM dexamethasone, 250M 1-methyl-3-isobutylxanthine, 0.01mg/ml 
transferrin, 0.2nM triiodothyronine, 20nM human insulin, 2M rosiglitazone, and 
100nM cortisol) was added. Four days later, the differentiation cocktail was 
replaced with maintenance medium (DMEM/F12, biotin, pantothenic acid, 
transferrin, insulin and cortisol). Cells were considered fully mature 14 days post-
differentiation. Adenoviruses were made as follows: The cDNA of the transgene 
of interest was first cloned into a pShuttle plasmid (Clontech, Mountain View, CA) 
and then subcloned into a molecular clone of E1-and E3-deleted human 
adenovirus serotype 5. This adenovirus plasmid backbone was modified from 
pAdX system (Clontech, Mountain View, CA) by introducing a green-white 
selection mechanism (281). The recombinant clones of adenovirus vector with 
the transgene of interest were selected through this green-white screening, 
confirmed by restriction enzyme analyses and rescued in 293 cells after 
restriction enzyme linearization and transfection. The recombinant virus is 
expanded and purified by standard CsCl gradient sedimentation followed by 
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dialysis for desalting (282). The HA control construct was made by inserting 3HA 
at Not1 and BamH1 sites of the 4124 base pair plasmid pShuttle Adeno vector. 
3HA Hig2 adenovirus plasmid DNA was made by inserting a full-length gene of 
Hig2 at restriction sites Blp1 (5’) and BamH1 (3’) of 3HA adeno viral plasmid 
DNA. 
 
Cell Imaging: Cells were fixed in 10% buffered formalin in PBS for 1 hour, 
blocked in 1% normal goat serum in PBS for 1hour at room temperature, 
incubated with Hig2 (1:100, Rockland Immunochemicals, (304)) for 2 hours at 
room temperature, incubated with fluorescent secondary 1:1000 for 1 hour, 
treated with Bodipy 493/503 (ThermoFisher, D-3922) at 1:10,000 for 15 minutes, 
and mounted with Prolong Gold with DAPI (Life Technologies). Cells were 
imaged at room temperature with a Solamere Technology Group modified 
Yokogawa CSU10 Spinning Disk Confocal with a Nikon TE-2000E2 inverted 
microscope at 60x.  
 
Histology: Tissues were isolated and fixed in 10% formalin, embedded in 
paraffin, sectioned, and stained with hematoxylin and eosin (H&E). The UMass 
Morphology Core performed the embedding and sectioning.  
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Statistical Analysis: Data were analyzed in GraphPad Prism 6 (GraphPad 
Software, Inc.). A two-tailed student’s t test with Welch’s Correction was used to 
compare two groups of data. Where indicated, data were analyzed using a one-
way ANOVA or a two-way ANOVA with repeated measures.  P<.05 was 
considered to be significant. The Grubb’s test was used to determine if there 
were statistical outliers and if an outlier was determined, it was removed from the 
statistical analysis. Variance was estimated using standard error of the mean. 
 
Results: 
Hig2 expression increases with adipogenesis and obesity. 
 To elucidate critical genes for human adipocyte biology, microarray 
analyses were performed on omental adipose tissue from human patients 
undergoing bariatric surgery after fractionation into adipocytes and SVF (301) 
and genes were sorted by adipocyte specificity. One of the top gene hits that 
displayed 10-fold enrichment in signal in the adipocyte fraction compared with 
SVF was Hig2 (Figure 3.1B). To validate this result, qRT-PCR was performed, 
and Hig2 expression 28-fold higher in human epididymal adipocytes (Figure 
3.1C) and 12-fold higher in human subcutaneous adipocytes (Figure 3.1D) 
compared with respective SVFs. Hig2 expression increased with lipid deposition 
in liver (304). To investigate whether this was also the case in adipose tissue, 
wild type animals were placed on a HFD for 20 weeks, and Hig2 expression in 
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epididymal white adipose tissue (eWAT) was measured by qRT-PCR. Hig2 
expression in eWAT of wild type animals doubled with high-fat-feeding (Figure 
3.1A).  
 As LD proteins often display increases in expression with adipogenic 
differentiation (176,183,185,193,212), Hig2 expression was also measured by 
qRT-PCR in two adipocyte cell lines upon adipogenic stimulation. In the murine 
3T3-L1 adipocyte cell line, Hig2 expression was unchanged with differentiation 
(Figure 3.1E); however, its expression was increased by 10-fold after 14 days of 
adipogenic differentiation in the human Simpson-Golabi-Behmel syndrome 
(SGBS) adipocyte cell line (Figure 3.1F). 
  
  
109 
 
 
Figure 3.1 Hig2 expression increases with adipogenesis and obesity. 
 
 
FIGURE 3.1 Hig2 expression increases with adipogenesis and obesity. A, 
C57BL/6J animals were fed HFD for 20 weeks, eWAT was isolated, RNA was 
extracted, and qRT-PCR was performed for Hig2 and normalized to 36B4. (***, 
p<.005, n=7-8). Data are represented as the mean + S.E. B-D Adipose tissue 
was isolated from patients undergoing bariatric surgery. B, microarray from 
omental adipose tissue. (#, p<.0001, n=6). C, D qRT-PCR was performed on 
indicated tissues for Hig2 and normalized to Rplp0. C, fractionated omental 
adipose tissue. (*, p<0.05, n=6-7). D, fractionated subcutaneous adipose tissue. 
(*, p<0.05, n=7-8). Data are represented as the mean + S.E. E, 3T3-L1 cells 
were differentiated, RNA was extracted on the indicated day, and qRT-PCR was 
performed for Hig2 and normalized to 36B4. (n=3-7). Data are represented as the 
mean + S.E. F, SGBS cells were differentiated, RNA was extracted on the 
indicated day, and qRT-PCR was performed for Hig2 and normalized to Rplp0. 
(*, p<0.05, one-way analysis of variance, n=3-7). Data are represented as the 
mean + S.E.  
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Hig2 localizes to LDs in human and mouse cultured adipocytes. 
 As Hig2 expression significantly increased with differentiation in SGBS 
cells, immunofluorescence for endogenous Hig2 was performed in SGBS cells 
on day 10, post-differentiation. Interestingly, Hig2 (green) localized around 
cellular structures (Figure 3.2A); staining confirmed that these structures were 
indeed LDs and that Hig2 (red) localized to Bodipy-positive (green) LDs, much 
like it did in primary hepatocytes, demonstrating that Hig2 is also a LD protein in 
human adipocytes (Figure 3.2B). To investigate whether this was the case in 
mouse adipocytes, mature 3T3-L1 adipocytes were infected with either HA 
control or HA-tagged Hig2 adenovirus and imaged. While the HA control 
adenovirus displayed a diffuse localization pattern, ectopically expressed Hig2 
appeared to localize to LDs in cultured mouse adipocytes (Figure 3.2C), 
demonstrating that Hig2 is a LD protein in mouse adipocytes.   
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FIGURE 3.2 Hig2 localizes to LDs in human and mouse cultured 
adipocytes. A-B, SGBS cells were fixed Day 10 post-differentiation. A, Cells 
were stained with Hig2 (green) and DAPI (blue). The two panels are two different 
representative fields. B, Cells were stained with Hig2 (red), Bodipy (green), and 
DAPI (blue). Left, merge of Hig2 and DAPI, right, merge of Hig2, Bodipy, and 
DAPI. C, Mature 3T3-L1 adipocytes were infected with HA control or HIG2-HA 
adenovirus, stimulated with 500M oleic acid complexed to fatty acid-free BSA 
for 30 minutes, fixed, and stained with HA (green) and DAPI (blue).  Left, HA 
control-infected cells; right, HIG2-HA infected cells. 
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Figure 3.2 Hig2 localizes to LDs in human and mouse cultured adipocytes. 
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Adipocyte-specific Hig2-deficient mice display adipocyte-specific deletion. 
 To further investigate the role of adipocyte-specific Hig2, mice with an 
adipocyte-specific Hig2 deficiency (Hig2AdKO) were generated by crossing a 
Hig2fl/fl mouse with an Adiponectin Cre+ mouse (Figure 3.3A). To determine 
whether the deletion was adipocyte-specific, eWAT and inguinal WAT (iWAT) 
were fractionated, adipocytes were isolated, and qRT-PCR was performed for 
Hig2. As expected, there was a significant 60% reduction in Hig2 mRNA 
expression in eWAT and 70% reduction in iWAT in Hig2AdKO animals compared 
with fl/fl littermate controls (Figure 3.3B). There was also a significant 50% 
reduction in Hig2 expression in whole BAT but no change in non-adipose tissues 
such as kidney and spleen, demonstrating that the deletion is specific to 
adipocytes (Figure 3.3C,D).  
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Figure 3.3 Adipocyte-specific Hig2-deficient mice display adipocyte-
specific Hig2 deletion. 
 
 
 
 
 
FIGURE 3.3 Adipocyte-specific Hig2-deficient mice display adipocyte-
specific deletion. A, schematic of adiponectin-cre-mediated Hig2 deletion. B-D, 
indicated tissues were isolated from fl/fl and Hig2AdKO mice, RNA was 
extracted, and qRT-PCR was performed for Hig2 and normalized to 36B4. B, 
isolated epididymal and inguinal adipocytes. (*, p=0.05, n=3-9). C, brown adipose 
tissue. (*, p<0.05, n=5-8). D, kidney and spleen. (**, p<.01, n=4-10). Data are 
represented as the mean + S.E.  
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Adipocyte-specific Hig2-deficient mice display improved glucose tolerance after 
HFD at 23°C. 
 To determine the role of adipocyte-specific Hig2 deficiency on whole body 
metabolism, Hig2AdKO and fl/fl animals were subjected to normal diet (ND) or 
high fat diet (HFD) for 16 weeks. There were no significant differences in body 
weight or insulin tolerance as measured by an insulin tolerance test (ITT) 
between genotypes in either feeding condition (Figure 3.4A,C), but Hig2AdKO 
animals had significantly improved glucose tolerance in the high-fat-fed condition 
as measured by a glucose tolerance test (GTT) (Figure 3.4B), suggesting that 
adipocyte Hig2 promotes glucose intolerance in diet-induced obesity. 
 Serum metabolites and liver triglyceride levels were measured in both ND 
and HFD conditions and, although there was a significant increase in fasted 
insulin in Hig2AdKO animals compared with fl/fl controls (2.7 + 0.4 ng/ml vs 1.4 + 
0.3 ng/ml) in the HFD-fed condition, there were no changes in serum adiponectin 
levels, serum TGs, serum NEFAs, serum glycerol or liver TGs (Table 3.4). 
Differences in the ND condition were also unremarkable, except for an increase 
in liver TGs in Hig2AdKO animals compared with controls (9.02 + 2.65g/ml vs 
17.9 + 2.05g/ml), (Table 3.1). It is unlikely that the increased fasting insulin in 
the 16 week HFD Hig2AdKO animals accounts for the improvements in glucose 
tolerance, as Hig2AdKO animals that were high-fat fed for 8 weeks display 
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improved glucose tolerance compared to fl/fl controls (Figure 3.4D), but no 
change in insulin levels during a GTT (Figure 3.4E). 
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Figure 3.4 Adipocyte-specific Hig2-deficient mice display improved glucose 
tolerance after HFD at 23°C. 
 
 
FIGURE 3.4 Adipocyte-specific Hig2-deficient mice display improved 
glucose tolerance after HFD at 23°C. A-C, fl/fl or Hig2AdKO animals were fed 
ND or HFD for 16 weeks. A, body weight curves. (n=8-20). B, glucose tolerance 
test. (*, p<0.05, **, p<.01, ***, p<.001, $, p<.005, two-way analysis of variance, 
n=5-13). C, insulin tolerance test. (n=4-13). Data are represented as the mean + 
S.E. D-E, fl/fl or Hig2AdKO animals were fed HFD for 8 weeks. D, glucose 
tolerance test. (*, p<0.05, **, p<.01, ***, p<.001, $, p<.005, two-way analysis of 
variance, n=8-13). E, insulin was measured 0 and 30 minutes-post glucose 
injection. (n=3-6). Data are represented as the mean + the S.E. 
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Table 3.1  
Liver cholesterol and serum metabolites were assessed from fl/fl or Hig2AdKO 
animals fed ND or HFD for 16 weeks at 23°C. (*, p<0.05, n=5-13). Data are the 
mean + S.E. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parameters
Hig2 fl/fl Hig2AdKO Hig2 fl/fl Hig2AdKO
Insulin (ng/ml) 1.441 + 0.486 0.794 + 0.271 1.436 + 0.258 2.743 + 0.395*
Adiponectin (g/ml) 7.209 + 0.225 7.456 + 0.263 8.315 + 0.708 9.052 + 0.684
Serum triglycerides (mg/dL) 77.05 + 4.176 75.94 + 5.418 92.42 + 8.409 88.64 + 5.818
Serum cholesterol (mg/dL) 303.1 + 21.11 314.7 + 29.15 401.1 + 34.42 330.9 + 53.42
NEFA (mmol/liter) 0.690 + 0.074 0.690 + 0.048 0.553 + 0.032 0.622 + 0.037
Serum glycerol (mg/ml) 0.056 + 0.003  0.053 + 0.03 0.054 + 0.004 0.056 + 0.004
Liver  triglycerides (g/mg) 9.018 + 2.652 17.89 + 2.054* 42.43 + 5.831 41.20 + 6.384
Normal Diet 16wks HFD
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Metabolic Cage parameters are unchanged in adipocyte-specific Hig2-deficient 
animals at 23°C. 
 As high fat-fed Hig2AdKO animals displayed improved glucose tolerance 
compared with fl/fl controls at 23°C, individually-housed obese animals were 
subjected to three days of metabolic cage analysis. Food intake was measured 
and found to be unchanged between the genotypes (Figure 3.5A). Furthermore, 
there were no differences between genotypes in daytime or nighttime physical 
activity (Figure 3.5B), oxygen consumption (Figure 3.5C), or carbon dioxide 
production (Figure 3.5D). Finally, respiratory exchange ratio (RER) and energy 
expenditure were calculated and found to be unchanged (Figure 3.5E, F).   
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Figure 3.5 Metabolic cage parameters are unchanged in adipocyte-specific 
Hig2-deficient animals at 23°C. 
 
 
 
FIGURE 3.5 Metabolic cage parameters are unchanged in adipocyte-
specific Hig2-deficient animals at 23°C. A-D, Metabolic cage analysis was 
performed over 3 days in fl/fl and Hig2AdKO mice that had been fed with HFD for 
16 weeks. A, food intake. B, physical activity. C, average VO2 consumption. D, 
average CO2 production. E, respiratory exchange ratio (RER). F, energy 
expenditure normalized to lean body mass. Data are represented as the mean + 
S.E. (n=4-6). Day (7am-7pm); Night, (7pm-7am).   
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Adipocyte-specific Hig2 deficiency alters adipose tissue distribution in HFD-fed 
mice at 23°C. 
 LD protein deficiencies alter lipid deposition in vivo 
(177,203,219,220,223,245). Thus, fat pad and liver weights of fl/fl and Hig2AdKO 
animals were examined. In chow-fed mice, eWAT and iWAT fat pad weights 
were unchanged between genotypes (Figure 3.6 A,B). However, upon HFD-
feeding, Hig2AdKO animals had significantly less eWAT weight compared with 
fl/fl controls (3.9 + .42% vs 5.7 + .24%), while iWAT weight was unchanged 
(Figure 3.6A,B). This reduction corresponded to a concomitant increase in liver 
weight from 2.7 + .07% of body weight in controls to 3.1 + .11% in Hig2AdKO 
animals (Figure 3.6D). Chow-fed Hig2AdKO animals also had significantly 
increased liver weight compared with fl/fl littermates (Figure 3.6C). 
 The reduction in eWAT weight suggests that Hig2 deficiency reduces 
adipocyte-specific fat deposition. Thus, H&E-stained histology from HFD animals 
was examined to determine whether there were visible alterations in AT and liver 
to complement the weight differences. While eWAT, iWAT, and liver histology 
appeared unchanged between the genotypes (Figure 3.6E,F,H), there was a 
striking visible reduction in lipids in BAT of Hig2AdKO animals compared with fl/fl 
controls (Figure 3.6G). There were no differences in BAT weight between 
genotypes in the ND or HFD- fed mice (Figure 3.6D). Taken together, these 
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results suggest that adipocyte-specific Hig2 deficiency alters adipose tissue 
distribution in obesity. 
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Figure 3.6 Adipocyte-specific Hig2 deficiency alters adipose tissue 
distribution in HFD-fed mice at 23°C. 
 
 
FIGURE 3.6 Adipocyte-specific Hig2 deficiency alters adipose tissue 
distribution in HFD-fed mice at 23°. A-H, fl/fl or Hig2AdKO animals were fed 
ND or HFD for 16 weeks. A-D, Tissues were weighed and normalized to body 
weight. A, eWAT. (**, p<0.01, n=5-13). B, iWAT. (n=5-14). C, BAT. (n=5-10). D, 
liver. (**, p<0.01, n=5-12). Data are represented as individual values + S.E. E-H, 
HFD tissues were sectioned and stained with H&E. E, eWAT. F, iWAT. G, BAT. 
H, Liver. 
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Thermoneutrality abrogates the improved glucose tolerance in adipocyte-specific 
Hig2-deficient mice. 
 Mice are often housed at 23°C, which presents a cold stress and 
persistent activation of thermogenic pathways. Cold stress increases 
catecholamine levels, thereby activating nonshivering thermogenesis in BAT and 
substantially increasing food intake and metabolic rate (60). Thus, it is critical to 
characterize mice at thermoneutrality (30°C), a temperature which poses no 
thermal stress and little BAT activation (105,300,305). Recently, it has been 
demonstrated that mice with LD protein deficiencies placed at thermoneutrality 
more closely phenocopy lipodystrophic syndromes in humans with mutations in 
LD protein genes (248). For these reasons, Hig2AdKO animals were fed chow or 
HFD for 8 weeks at 23°C, then moved to 30°C for four weeks, and metabolic 
parameters were assessed.   
 While there were no differences in body weight or ITTs between 
genotypes when placed in thermoneutrality (Figure 3.7A,C), Hig2AdKO animals 
surprisingly had a significantly worsened glucose tolerance compared with fl/fl 
controls on a HFD (Figure 3.7B). This represented a marked reversal in glucose 
tolerance that was dependent on housing temperature, which is similar to the 
phenotype of Fsp27-deficient animals (248).  
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Figure 3.7 Thermoneutrality abrogates the improved glucose tolerance in 
adipocyte-specific Hig2-deficient mice. 
 
 
FIGURE 3.7 Thermoneutrality abrogates the improved glucose tolerance in 
adipocyte-specific Hig2-deficient mice. A-C, fl/fl or Hig2AdKO animals were 
fed ND or HFD for 8 weeks, then moved to 30°C for 4 weeks. A, body weight 
curves at 30°C. (n=3-9). B, glucose tolerance test. (*, p<0.05, $, p<0.05, two-way 
analysis of variance, n=3-10). C, insulin tolerance test. (n=3-5). Data are 
represented as the mean + S.E.  
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Thermoneutrality abrogates the altered fat distribution in Adipocyte-specific Hig2-
deficient mice. 
 As glucose tolerance on HFD was worsened with thermoneutral housing, 
alterations in fat distribution were also assessed. Indeed, the reduction in eWAT 
weight that was observed in Hig2AdKO animals at 23°C was abrogated when the 
animals were placed at thermoneutrality (Figure 3.8A). Furthermore, the increase 
in liver weight that was observed in Hig2AdKO animals at 23°C was also 
suppressed (Figure 3.8D); however, there continued to be no difference in iWAT 
or BAT weight between genotypes (3.8B,C). Additionally, H&E-stained histology 
sections of eWAT, iWAT, BAT, and liver were examined and no visual 
differences were observed between fl/fl and Hig2AdKO animals (Figure 3.8E-H), 
a striking contrast from 23°C, at which temperature the Hig2AdKO mouse BAT 
was cleared of lipids (Figure 3.8G). Serum and liver biochemical analyses were 
additionally examined in thermoneutrality and no differences were found between 
genotypes for all measured parameters (Table 3.2).Thus, all phenotypic 
differences in fl/fl vs. Hig2AdKO mice were abrogated at thermoneutrality 
(glucose tolerance, eWAT weight, liver weight, BAT lipid content), which 
suggests that these parameters may be mediated by BAT function that is 
dependent on activation of BAT by cold stress.  
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Figure 3.8 Thermoneutrality abrogates the altered fat distribution in 
Adipocyte-specific Hig2-deficient mice. 
 
 
 
FIGURE 3.8 Thermoneutrality abrogates the altered fat distribution in 
Adipocyte-specific Hig2-deficient mice. A-H, fl/fl or Hig2AdKO animals were 
fed ND or HFD for 8 weeks, then moved to 30°C for 4 weeks. A-D, Tissues were 
weighed and normalized to body weight. A, eWAT. (n=3-10). B, iWAT. (n=3-10). 
C, BAT. (n=3-10). D, Liver. (n=3-10). Data are represented as individual values + 
S.E. E-H, the indicated tissues were sectioned and stained with H&E. E, eWAT. 
F, iWAT. G, BAT. H, Liver. 
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Table 3.2 
 
Liver cholesterol and serum metabolites were assessed from fl/fl or Hig2AdKO 
animals fed ND or HFD for 8 weeks then moved to 30°C for 4 weeks. (n=3-11). 
Data are the mean + S.E. ND, not determined. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parameters
Hig2 fl/fl Hig2AdKO Hig2 fl/fl Hig2AdKO
Insulin (ng/ml) ND ND 2.956 + 0.577 3.607 + 0.304
Serum triglycerides (mg/dL) 101.1 + 42.67 128.3 + 23.05 89.03 + 10.72 89.99 + 8.815
Serum cholesterol (mg/dL) 678.3 + 68.31 685.9 + 75.38 1059 + 57.95 1152 + 22.41
NEFA (mmol/liter) 0.2132 + 0.071 0.211 + 0.032 0.312 + 0.046 0.309 + 0.051
Serum Glycerol (mg/ml) 0.021 + 0.001 0.032 + 0.006 0.054 + 0.005 0.056 + 0.006
Liver triglycerides (g/mg) 7.277 + 0.4573 8.222 + 1.544 97.23 + 8.578 88.36 + 4.505
Liver cholesterol (g/mg) 0.899 + 0.191 0.868 + 0.087 0.820 + 0.093 0.720 + 0.078
Normal Diet 12wks HFD
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Adipocyte-specific Hig2 deficiency increases phosphorylated HSL, but does not 
alter ex vivo glycerol release at 23°C. 
 Hig2 deficiency was shown in Chapter II to increase lipolysis and -
oxidation in hepatocytes (304); thus, the role of Hig2 deficiency in adipocytes to 
control these parameters was investigated. Ex vivo glycerol release was 
measured from eWAT explants of fl/fl and Hig2AdKO animals in basal and 
isoproterenol-stimulated conditions, and no difference was found between 
genotypes (Figure 3.9A). Although there was no change in ex vivo basal or 
isoproterenol-stimulated glycerol release (Figure 3.9A), lipolytic gene expression 
was measured in eWAT to determine whether adipocyte-specific Hig2 deficiency 
altered lipolytic gene expression in vivo. There were significant approximately 2-
fold expression increases in the lipase ATGL, as well as the LD protein Fsp27, 
both of which are responsive to increases in lipolysis (Figure 3.9B) (93,306,307). 
Furthermore, the LD protein Perilipin 1 was increased by 2-fold (Figure 3.9B), 
there was a non-significant trend to increased expression of the lipase HSL, and 
the two modulators of ATGL activity, Cgi58 and G0s2 were unchanged (Figure 
3.8B). When immunoblots were performed on eWAT lysates from fl/fl and 
Hig2AdKO animals, phosphorylated HSL (pHsl) exhibited an approximately 5-fold 
increase in the Hig2AdKO mice compared with controls. This phosphorylation 
increase was specific to HSL, as the phosphorylation of other PKA substrates 
was unchanged between genotypes (Figure 3.9E). ATGL and total HSL (tHsl) 
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protein levels were also unchanged (Figure 3.9E,F), suggesting that adipocyte-
specific Hig2 enhances some aspects of lipolytic signaling in vivo, independent of 
increases in glycerol release ex vivo.  
 To further probe these gene expression changes and because of the 
striking BAT lipid clearance observed in Hig2AdKO animals at 23°C, Ucp1, a 
gene critical for BAT function and Prdm16, a transcription factor essential for 
BAT identity (48), were measured in BAT by qRT-PCR; however, their 
expression was unchanged between genotypes (Figure 3.9D). Furthermore, the 
same genes, as indication of a BAT-like gene expression program (48), were 
assessed in iWAT but were also unchanged (Figure 3.9C).  
 These data suggest that adipocyte-specific Hig2 deficiency selectively 
increased phosphorylated HSL in eWAT in vivo, thus, it was assessed whether 
thermoneutrality, which abrogates the improvement in glucose tolerance in the 
Hig2AdKO animals (Figure 3.7) would also abrogate this increase. 
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Figure 3.9 Adipocyte-specific Hig2 deficiency increases phosphorylated 
HSL, but does not alter ex vivo glycerol release at 23°C. 
 
FIGURE 3.9 Adipocyte-specific Hig2 deficiency increases phosphorylated 
HSL, but does not alter ex vivo glycerol release at 23°C. A-G, fl/fl or 
Hig2AdKO animals were fed ND or HFD for 16 weeks. A, ex vivo lipolysis of 
eWAT. (n=3-5). Data are represented as the mean + S.E. B-D, indicated tissues 
were isolated, RNA was extracted, and qRT-PCR was performed for the 
indicated genes and normalized to 36B4. B, HFD eWAT. (+, p<0.09, n=5-8). C, 
HFD iWAT. (n=4-10). D, HFD BAT. (n=4-8). Data are represented as the mean + 
S.E. E, representative immunoblots from eWAT of phospho Hsl, total Hsl, Atgl, 
Tubulin, and phospho PKA substrate. IB, immunoblot; pHsl, phospho Hsl; tHsl, 
total Hsl. F, quantification of immunoblots from E, normalized to total HSL or 
Tubulin and fl/fl controls. ($, p=0.08, n=5). Data are represented as the mean + 
S.E. 
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Thermoneutrality abrogates the increase in phosphorylated HSL in adipocyte-
specific Hig2-deficient mice. 
 To determine whether thermoneutrality abrogated the differences that 
were observed in Hig2AdKO eWAT (Figure 3.9), an ex vivo lipolysis assay, qRT-
PCR and immunoblots of lipolytic signaling genes were performed on eWAT from 
fl/fl and Hig2AdKO HFD animals housed at 30°C for 4 weeks. Similar to 23°C, 
there were no differences between genotypes in ex vivo glycerol release of 
eWAT explants (Figure 3.10A).  The increases in ATGL, Perilipin1, and Fsp27 
gene expression that were observed in Hig2AdKO eWAT at 23°C were all 
blunted at thermoneutrality, and expression levels of HSL, Cgi58, and G0s2 also 
remained unchanged (Figure 3.10B). Strikingly, the increase in pHSL that was 
observed at 23°C in Hig2AdKO mice was also suppressed in eWAT after 
thermoneutrality (Figure 3.10C,D), and tHSL, ATGL, and pPKA substrate protein 
levels remained unchanged (Figure 3.10B,C). These data suggest that 
thermoneutrality abrogates the increase in phosphorylated HSL in Hig2AdKO 
animals, which may partially explain the worsened glucose tolerance of these 
animals at thermoneutrality (Figure 3.7B).  
 
 
 
 
133 
 
 
Figure 3.10 Thermoneutrality abrogates the increase in phosphorylated 
HSL in adipocyte-specific Hig2-deficient mice. 
 
 
FIGURE 3.10 Thermoneutrality abrogates the increase in phosphorylated 
HSL in adipocyte-specific Hig2-deficient mice. A-G, fl/fl or Hig2AdKO animals 
were fed ND or HFD for 8 weeks, and then moved to 30°C for 4 weeks. A, ex 
vivo lipolysis of eWAT. (n=3-10). Data are represented as the mean + S.E. B, 
eWAT was isolated from HFD animals, RNA was extracted, and qRT-PCR was 
performed for the indicated genes and normalized to 36B4. (n=4). Data are 
represented as the mean + S.E. C, representative immunoblots (IB) from eWAT 
of phospho Hsl (pHsl), total Hsl (tHsl), Atgl, Tubulin, and phospho PKA substrate. 
IB, immunoblot; Ctl, control; KO, Hig2AdKO. D, quantification of immunoblots 
from E, normalized to total HSL or Tubulin and fl/fl controls. (n=4-5). Data are 
represented as the mean + S.E. 
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Brown adipocyte-specific Hig2-deficient mice display brown adipocyte-specific 
deletion. 
 
 Thermoneutrality abrogated the improvement in glucose tolerance 
mediated by adipocyte-specific Hig2 deficiency and thermoneutrality reduces 
both lipolysis and brown fat activity (48). Furthermore, thermoneutrality 
abrogated the increase in phosphorylated HSL mediated by Hig2 deficiency 
(Figure 3.10). Thus, to elucidate the role of Hig2 specifically in the brown 
adipocyte, Hig2fl/fl animals were crossed to brown and beige/brite adipocyte-
specific Ucp1 Cre+ animals to generate Hig2 brown adipocyte-specific knockout 
animals (Hig2BATKO) (Figure 3.11A). 
 Tissues were isolated from fl/fl and Hig2BATKO animals to assess 
deletion specificity. There was a significant reduction in Hig2 mRNA in whole 
BAT as measured by qRT-PCR (Figure 3.11B), but no reduction in other tissues 
such as white adipocytes, spleen, or kidney (Figure 3.11C,D), demonstrating that 
the deletion is specific. Interestingly, Hig2 expression was upregulated by 
approximately 7-fold in eWAT adipocytes of Hig2BATKO animals compared with 
floxed controls (3.11C). 
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Figure 3.11 Brown adipocyte-specific Hig2 deficient mice display brown 
adipocyte-specific deletion. 
 
 
 
FIGURE 3.11 Brown adipocyte-specific Hig2-deficient mice display brown 
adipocyte-specific deletion. A, schematic of ucp1-cre-mediated Hig2 deletion. 
B-D indicated tissues were isolated from fl/fl and Hig2BATKO mice, RNA was 
extracted, and qRT-PCR was performed for Hig2 and normalized to 36B4. B, 
brown adipose tissue. (#, p<.001, n=7). C, isolated epididymal and inguinal 
adipocytes. (**, p<.01, n=3-7). D, kidney and spleen. (n=3-8). Data are 
represented as the mean + S.E.  
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Brown adipocyte-specific Hig2 deficiency improves glucose tolerance under high 
fat-fed conditions at 23°C. 
 To evaluate the role of brown adipocyte-specific Hig2 deficiency on whole 
body metabolism at 23°C, fl/fl and Hig2BATKO animals were placed on HFD for 
8 weeks and metabolic parameters were assessed. There were no differences in 
body weight or insulin tolerance between the genotypes (Figure 3.12A,C). 
However, when challenged with a GTT, Hig2BATKO animals were significantly 
more glucose tolerant compared to their fl/fl control littermates (Figure 3.12B), 
similar to the Hig2AdKO animals (Figure 3.4). Finally, no changes in ex vivo 
glycerol release from eWAT explants of fl/fl and Hig2BATKO animals were 
observed (Figure 3.12D). Taken together, these data suggest that the 
improvement in glucose tolerance in Hig2AdKO animals can be attributed to 
brown adipocyte-specific Hig2 deficiency.  
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Figure 3.12 Brown adipocyte-specific Hig2 deficiency improves glucose 
tolerance under high fat-fed conditions at 23°C. 
 
 
FIGURE 3.12 Brown adipocyte-specific Hig2 deficiency improves glucose 
tolerance under high-fat-fed conditions. A-D, fl/fl or Hig2BATKO animals were 
fed HFD for 8 weeks. A, body weight curves. (n=8-10). B, glucose tolerance test. 
(*, p<0.05, **, p<.01, $, p<.05, two-way analysis of variance, n=8-10). C, insulin 
tolerance test. (n=8-10). D, ex vivo lipolysis of eWAT. (n=3-8).  Data are 
represented as the mean + S.E.  
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Brown adipocyte-specific Hig2 deficiency does not alter adipose tissue 
distribution at 23°C. 
 To determine if Hig2 deficiency in brown adipocytes was responsible for 
the reduced eWAT weight and increased liver weight in Hig2AdKO animals, liver 
and fat pads were weighed from fl/fl and Hig2BATKO animals after 8 weeks of 
HFD at 23°C. eWAT, iWAT, BAT and liver weights were unchanged between 
genotypes (Figure 3.13A-D). 
 In accordance with these results, H&E-stained histological sections of 
eWAT, iWAT, BAT, and liver appeared to be unchanged between Hig2BATKO 
animals and fl/fl controls (Figure 3.13E-H). Serum biochemical analyses were 
also measured and displayed no remarkable differences between genotypes 
(Table 3.3). Taken together, these results demonstrate that brown adipocyte-
specific Hig2 deficiency alone is not sufficient to redistribute fat deposition in 
WAT as observed in the Hig2AdKO animals. 
 
 
 
 
 
 
 
 
 
 
 
139 
 
 
Figure 3.13 Brown adipocyte-specific Hig2 deficiency does not alter 
adipose tissue weight after HFD at 23°C. 
 
 
 
FIGURE 3.13 Brown adipocyte-specific Hig2 deficiency does not alter 
adipose tissue weight after HFD at 23°C. A-H, fl/fl or Hig2BATKO animals 
were fed HFD for 8 weeks. A-D, Tissues were weighed and normalized to body 
weight. A, eWAT. (n=8-10). B, iWAT. (n=8-10). C, BAT. (n=8-10). D, liver. (n=8-
10). Data are represented as individual values + S.E. E-H, the indicated tissues 
were sectioned and stained with H&E. E, eWAT. F, iWAT. G, BAT. H, Liver. 
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Table 3.3 
Liver cholesterol and serum metabolites were assessed from fl/fl or Hig2BATKO 
animals fed HFD for 8 weeks at 23°C. (n=3-8). Data are the mean + S.E.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parameters
Hig2 fl/fl Hig2BATKO
Serum triglycerides (mg/dL) 114.7 + 17.81 83.83 + 8.038
NEFA (mmol/liter) 0.688 + 0.054 0.599 + 0.064
Serum Glycerol (mg/ml) 0.044 + 0.003 0.050 + 0.004
Liver triglycerides (g/mg) 31.97 + 4.869 31.40 + 2.539
8wks HFD
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Discussion: 
 The results in this chapter show that Hig2 localized to LDs (Figure 3.2) 
and its expression increased with adipogenic differentiation in the human SGBS 
adipocyte cell line, and that it is a highly expressed gene in isolated adipocytes 
from human patients (Figure 3.1). Hig2 deficiency in adipocytes (Figure 3.3) of 
mice reduced eWAT mass, largely cleared BAT of lipids, and improved HFD-
mediated glucose intolerance in vivo (Figure 3.4, 3.6, Table 3.1). Interestingly, 
these improvements were abrogated when the animals were placed at 
thermoneutrality for 4 weeks (Figure 3.7, 3.8, Table 3.2), suggesting that brown 
fat activity or other physiological responses to cold stress mediated these effects. 
 To test that hypothesis, lipolytic signaling and ex vivo glycerol release 
were measured in eWAT from animals housed at room temperature and 
thermoneutrality. Although glycerol release was unchanged between genotypes, 
strikingly, phosphorylation of HSL was significantly increased in eWAT of 
Hig2AdKO animals compared with controls (Figure 3.9). This increase in pHSL 
was abolished at thermoneutrality (Figure 3.10); thus, the increase in pHSL in 
Hig2AdKO animals is associated with fat redistribution (Figure 3.6) and 
improvement in glucose tolerance (Figure 3.4) at room temperature, but a 
causative connection is not clear. Although insulin levels are significantly 
increased in Hig2AdKO animals with 16 week high-fat feeding (Table 3.1), they 
are likely not the cause of the improved glucose tolerance in these animals, as 
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glucose tolerance is also improved in Hig2AdKO animals fed HFD for 8 weeks, a 
time point when insulin levels are unchanged (Figure 3.4).  
 Finally, to examine the role of brown-adipocyte-specific Hig2, Hig2BATKO 
animals were generated and metabolically characterized. These animals 
displayed no improvements in serum parameters, histology, or adipose tissue 
distribution, but had significantly improved glucose tolerance, suggesting that 
brown adipocytes alone have little role to regulate the altered lipid deposition in 
eWAT or clearing of BAT lipids in Hig2AdKO animals, but play a significant role 
in the metabolic improvements that were observed (Figure 3.12, 3.13, Table 3.3). 
The mechanism whereby brown adipocyte-specific Hig2-deficiency prevents 
obesity-associated glucose intolerance is currently unclear. Unchanged food 
intake, oxygen consumption, energy expenditure, and RER in the Hig2AdKO 
animals (Figure 3.5) suggest that improvements may be mediated independent 
of BAT thermogenesis. One possibility points to the putative endocrine function 
of BAT. Recent experiments suggest that, in addition to its thermogenic 
properties, activated BAT may function as an endocrine organ and can secrete 
beneficial molecules that improve overall metabolic health (308-312). For 
instance, transplanting BAT into WAT of diabetic mice promoted adipogenesis 
and restored euglycemia (313). Taken together, these data suggest that Hig2 
localizes to LD in human and mouse adipocytes that adipocyte-specific Hig2 
promotes glucose intolerance in mice. 
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 Although some of these data point towards inhibition of adipose tissue 
lipolysis as a potential mechanism for Hig2-mediated lipid deposition, much like 
the hepatocyte-specific mechanism, the exact mechanistic details need to be 
discerned and are still an area of active investigation. As the most striking 
change is the induction of pHSL, Hig2 could somehow be acting directly on HSL 
to prevent that activation. Interestingly, although pHSL is significantly increased 
in the eWAT of Hig2AdKO animals, other readouts of lipolytic stimulation, such 
as pPKA substrate proteins, ex vivo glycerol release, serum NEFAs, and serum 
glycerol are all unchanged (Figure 3.9, Table 3.1). These perplexing results raise 
several possibilities. First, the unchanged ex vivo glycerol release suggests that 
there may be crosstalk between multiple tissues in vivo and that this crosstalk is 
necessary for increased lipolysis in the eWAT as manifested by a reduction in its 
pad weight. This is underscored by the fact that adipocyte-specific Hig2 
deficiency increases liver weight and clears lipids in BAT and thus redistributes 
lipids throughout tissues in vivo. Second, the lack of change in lipolysis readouts 
in serum suggests that Hig2 may regulate lipolysis locally; thus, these alterations 
are not substantial enough to be detected systemically. Third, Hig2 could be 
promoting lipid deposition by an entirely different mechanism than lipolytic 
inhibition.  
 Metabolic characterization of the Hig2BATKO animals suggests that 
brown adipocyte-specific deficiency of Hig2 is not sufficient to alter fat distribution 
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of WAT, but improves diet-mediated glucose intolerance. Future experiments 
targeting Hig2 specifically in white adipocytes would be useful to determine its 
true contribution to the phenotype of Hig2AdKO animals. As crosstalk has 
already been suggested, it might be true that Hig2 deletion in both brown and 
white adipocytes is necessary to mediate the fat redistribution, but the 
improvements observed in glucose tolerance are solely mediated by brown 
adipocytes. 
 Thermoneutrality experiments, which more accurately represent human 
clothing conditions, demonstrate that adipocyte-specific Hig2 deletion is 
detrimental to metabolic health (Figure 3.7). As Hig2 is localized to LDs in human 
adipocytes and is highly expressed in adipocytes of human patients (Figure 
3.1,3.2), it will be interesting to investigate whether there are human mutations in 
Hig2, much like the canonical LD proteins Perilipin 1, and Fsp27/Cidec 
(251,252,298), and if these mutations cause partial lipodystrophy and metabolic 
dysregulation. Future experiments to challenge the Hig2AdKO animals with cold 
exposure to evaluate glucose tolerance would be insightful due to hyper-
activation of lipolysis and BAT at these temperatures (48).  
 In summary, Chapters II and III demonstrated that Hig2 is a ubiquitously 
expressed gene and its expression promotes lipid deposition and diet-induced 
glucose intolerance in adipose tissue and liver. Thus, it will be of interest to 
investigate the role of Hig2 in other tissues. LDs are relevant in a large variety of 
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cells; thus, the role of Hig2 in lipid deposition in other tissues is still largely 
unanswered and is an active area of investigation. 
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CHAPTER IV: Final summary, conclusions, and future directions 
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 Proper adipose tissue lipid sequestration is critical for the prevention of 
lipotoxicity, dyslipidemia, and ectopic lipid deposition. Thus, our lab is particularly 
interested in novel regulators of lipid storage in adipocytes (204,215). 
Furthermore, elucidating hepatocyte-specific mechanisms that promote liver 
steatosis could provide therapeutic targets to prevent the initial and reversible 
stage of NAFLD. One potential regulator of adipocyte lipid storage and hepatic 
steatosis is the LD protein Hig2. Work presented here was aimed at answering 
the following two questions: 
1) Does Hig2 function as a canonical LD protein in adipose tissue or 
liver and promote TG deposition by inhibition of lipolysis?  
2) What is the contribution of hepatocyte and adipocyte-specific Hig2 to 
whole body metabolism?  
 To answer those questions in liver, I first ectopically expressed a GFP-
tagged Hig2 in primary hepatocytes and determined that GFP-Hig2 localized to 
Oil Red-O positive LDs (Figure 2.1). This localization was dependent upon its 
previously identified “LD-targeting domain” (Figure 2.1) (263), as a truncated 
mutant no longer localized to LDs when ectopically expressed in hepatocytes 
(Figure 2.1). To determine if Hig2 expression promoted lipid deposition, I 
overexpressed Hig2 in primary murine hepatocytes, extracted TGs, and 
determined that Hig2 overexpression increased TG levels (Figure 2.2). 
Conversely, using a tamoxifen-inducible cre model, I inducibly deleted Hig2 from 
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hepatocytes in culture and determined that Hig2-deficient hepatocytes displayed 
reduced LD size, LD number, and TG content (Figure 2.3,2.4). To elucidate the 
role of hepatocyte-specific Hig2 in whole body metabolism, I used an albumin 
promoter-driven cre recombinase to delete Hig2 specifically in hepatocytes 
(Figure 2.5). By the standard measures of metabolic characterization (insulin 
tolerance test, glucose tolerance test, plasma and liver biochemistry, organ 
weights, histology), I determined that hepatocyte-specific Hig2 deletion improved 
glucose tolerance in chow-fed and HFD-fed mice and reduced liver weight and 
liver TGs in chow-fed mice (Figure 2.6). Furthermore, to elucidate the 
mechanism whereby Hig2 promoted lipid deposition, I measured expression of 
lipid handling genes in chow-fed control and Hig2-deficient livers and found to 
them be unchanged (Figure 2.7). This suggested that Hig2 deficiency may alter 
lipid flux, independent of gene expression changes. To investigate lipid flux, I 
performed tracer experiments with [3H] oleic acid and found that Hig2-deficient 
hepatocytes had decreased uptake of tracer lipids, increased production of acid-
soluble oxidation products and increased turnover of tracer lipids, suggesting that 
Hig2 deficiency increases lipolysis and -oxidation (Figure 2.8). Thus, my data 
suggest the answers to the two questions above in liver are: First, Hig2 does 
function as a canonical LD protein in hepatocytes and promotes TG deposition 
by inhibiting lipolysis. Second, hepatocyte-specific Hig2 promotes hepatic lipid 
deposition and glucose intolerance.   
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 To answer the two questions in adipose tissue, I first imaged endogenous 
Hig2 in the human SGBS adipocyte cell line and determined that Hig2 localized 
to Bodipy-positive LDs (Figure 3.2). Its expression in SGBS also increased with 
adipogenic differentiation, similar to other canonical LD proteins (Figure 3.1). To 
elucidate the role of adipocyte-specific Hig2 and determine if adipocyte-specific 
Hig2 deficiency altered lipolysis, I used an adiponectin promoter-driven cre to 
delete Hig2 specifically in adipocytes (Figure 3.3).  By the standard measures of 
metabolic characterization (insulin tolerance test, glucose tolerance test, plasma 
and liver biochemistry, organ weights, histology), I determined that adipocyte-
specific Hig2 deficient animals had improved glucose tolerance, reduced eWAT 
weight, and BAT that was largely cleared of lipids upon HFD feeding (Figure 3.4, 
3.6). An increase in phosphorylated HSL was present in the adipocyte-specific 
Hig2-deficient animals (Figure 3.9), although serum NEFAs and ex vivo glycerol 
release were unchanged (Table 3.1, Figure 3.9), suggesting that adipocyte-
specific Hig2 deficiency may not alter lipolysis. Metabolic improvements and the 
increase in pHSL were largely abrogated when adipocyte-specific Hig2-deficient 
animals were moved to 30°C thermoneutrality, a temperature with minimal 
thermal stress and little BAT activation (Figure 3.7, 3.8, 3.10). To assess the role 
of brown adipocyte-specific Hig2 in whole body metabolism, I used a UCP1 
promoter-driven cre to delete Hig2 specifically in brown adipocytes (Figure 3.11). 
I determined that brown adipocyte-specific Hig2 deficient animals had improved 
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glucose tolerance, but no changes in fat pad distribution, suggesting that brown 
adipocyte-specific Hig2 deficiency may specifically mediate the glucose tolerance 
improvements in adipocyte-specific Hig2-deficient animals (Figure 3.12, 3.13). 
Thus, my data suggest the answers to the two questions above in adipose tissue 
are: First, Hig2 does function as a LD protein in adipocytes, but may not promote 
TG deposition by inhibiting lipolysis. Second, adipocyte-specific Hig2 promotes 
adipose tissue lipid deposition and glucose intolerance.   
 In summary, the data in this thesis confirm that Hig2 is indeed a LD-
localized protein in adipocytes and hepatocytes. Furthermore, the studies 
advance our understanding of the role of Hig2 as a LD protein that promotes lipid 
deposition and diet-induced glucose intolerance in two highly metabolically active 
tissues, liver and adipose tissue (Table 4.1), suggesting that Hig2 is a promising 
therapeutic target for the prevention of obesity and hepatic steatosis in NAFLD.  
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Table 4.1  
 
The phenotypes for all metabolically characterized Hig2 knockout animal models 
are summarized above. N/A; not applicable, HFD; high fat diet, GTT; glucose 
tolerance test, TG; triglyceride, eWAT; epididymal white adipose tissue, BAT; 
brown adipose tissue, RER; respiratory exchange ratio. 
 
 
 
 
 
 
 
 
 
 
Hig2LKO Hig2AdKO Hig2BATKO
Cre Promoter Albumin Adiponectin Ucp1
Tissue Deleted Hepatocytes Adipocytes Brown and Beige/Brite Adipocytes
23°C
Chow Fed Improved GTT Increased liver weight No change
Reduced liver weight
Reduced liver TG
HFD-Fed Improved GTT Improved GTT Improved GTT
No change liver weight Increased liver weight No change liver weight
No change liver TG Decreased eWAT weight No change eWAT weight
BAT cleared of lipids No change BAT lipids
No change RER, energy expenditure
30°C
Chow Fed N/A No change N/A
HFD-Fed N/A Worsened GTT N/A
No change liver weight
No change eWAT weight
No change BAT
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A role for Hig2 as a LD protein in hepatocytes 
 This section will discuss my interpretations, potential pitfalls, and future 
directions for the studies presented in Chapter II. Hig2 localized to LDs in the 
HeLa and Huh7 human cancer cell lines (263); thus, I hypothesized that Hig2 
could act as a LD protein in metabolically active tissues if it were expressed 
there. I performed expression profiling of murine Hig2 and found that Hig2 was 
indeed expressed in a variety of mouse tissues (Figure 2.10), including liver, thus 
I decided to evaluate the role of Hig2 in hepatic lipid deposition as a potential 
therapeutic target for NAFLD. One caveat of this experiment is that I profiled the 
mRNA expression of Hig2, which could differ from Hig2 protein levels. To more 
accurately characterize tissue-specific Hig2 levels, western blots should be 
performed in the future. As Hig2 was expressed in liver, I hypothesized that Hig2 
may act as a LD protein in hepatocytes and promote lipid deposition. 
 To begin to address my hypothesis, I ectopically expressed a GFP-tagged 
Hig2 in primary mouse hepatocytes and determined that Hig2 localized to Oil-
Red-O positive LDs (Figure 2.1B). The concerns with this experiment are one, 
the ectopic expression of Hig2 and two, that a 7kDa protein (Hig2) is tagged with 
a 27kDa protein (GFP), both of which may alter its localization. To begin to 
address these concerns, I GFP tagged Hig2 on its N and C terminus and 
expressed both GFP-Hig2 (Figure 2.1B) and Hig2-GFP (not shown) in primary 
hepatocytes and found that they both localize to LDs, while GFP alone did not 
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(Figure 2.1B). The ideal experiment would be to image endogenous Hig2 in 
primary mouse hepatocytes, but both commercial antibodies and the antibody we 
synthesized in conjunction with Rockland Immunochemicals are not sufficiently 
sensitive for immunofluorescence in hepatocytes. Additionally, biochemical 
analyses, such as cell fractionation and western blotting should be performed to 
confirm the LD localization of Hig2. I was able to confirm that the 28 N-terminal 
AA are required for LD localization of Hig2 (Figure 2.1A) (263), as when I 
ectopically expressed a truncated Hig2-GFP mutant and imaged by microscopy, 
it no longer localized to LDs (Figure 2.1B). As I determined that Hig2 localized to 
LDs in hepatocytes dependent upon its N terminal LD-targeting domain, I 
proceeded to characterize it as a LD protein in hepatocytes.  
 Expression of liver-specific LD proteins, such as Fsp27 and Cidea are 
highly  induced upon lipid deposition in liver (200). Thus, I measured the 
expression of Hig2 in fasting and diet-induced obesity, two models of increased 
liver lipid content, and found its expression to be significantly increased in both 
conditions (Figure 2.1C,D). As fasting increases hepatic PPARα expression (314) 
and Hig2 has been shown to be regulated by PPARα (267), PPARα likely 
mediates the increase in Hig2 expression in fasted mouse liver. The upstream 
regulator of hepatic Hig2 expression in obesity is currently unknown. I then 
hypothesized that modifying Hig2 expression would alter lipid deposition in 
hepatocytes. To answer this question, I infected primary mouse hepatocytes with 
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an HA-tagged Hig2 adenovirus and found that Hig2 was indeed overexpressed 
(Figure 2.2B) and that this overexpression increased TG content (Figure 2.2C). 
One can argue that overexpression experiments are highly artificial, although the 
result was additionally confirmed by another group that found that AAV-mediated 
hepatic Hig2 overexpression promoted steatosis in mice (267). To address 
overexpression concerns, I also wanted to delete Hig2 in isolated hepatocytes 
and evaluate TG levels and LDs. Thus, I deleted Hig2 using a tamoxifen-
inducible ubiquitously expressed cre recombinase (Figure 2.3A) and confirmed 
that Hig2 was successfully deleted (Figure 2.3C,D). Using imaging analysis and 
TG extraction, I found that Hig2-deficient hepatocytes had less TGs (Figure 
2.3E), fewer LDs (Figure 2.4A,B) and that the remaining LDs were smaller 
(Figure 2.4 C). These results were opposite of the overexpression results, further 
validating the hypothesis that hepatocyte-specific Hig2 expression promotes lipid 
deposition. As tamoxifen treatment can have side effects, I treated control 
hepatocytes with tamoxifen and imaged them to determine that tamoxifen 
treatment alone does not reduce TG content (Figure 2.4D). Additionally, I 
obtained the same results by using a hepatocyte-specific constitutively-
expressed albumin cre recombinase to delete Hig2 (Figure 2.8A).   
 As Hig2 localized to LDs in hepatocytes and promoted lipid deposition, I 
strove to assess if Hig2 inhibited lipolysis and the role of hepatocyte-specific Hig2 
deficiency on whole body metabolism. Considering Hig2-deficient hepatocytes 
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displayed reduced TG levels and LD number, I hypothesized that liver-specific 
Hig2 deficient animals would have reduced liver lipids and improved metabolic 
parameters when challenged with HFD, as hepatic steatosis is often correlated 
with insulin resistance and metabolic disease (274). To address this hypothesis, I 
derived hepatocyte-specific Hig2-deficient (Hig2LKO) mice using a hepatocyte 
specific albumin cre recombinase (Figure 2.5A) and confirmed that these animals 
displayed hepatocyte-specific Hig2 deletion (Figure 2.5 B,C,D). I challenged 
these mice with HFD and assessed their metabolic parameters (glucose 
tolerance test, insulin tolerance test, serum and liver biochemistry) and found that 
Hig2LKO animals displayed improved glucose tolerance when fed normal chow 
and HFD (Figure 2.6B), as I had hypothesized. I was surprised to find that this 
improvement in glucose tolerance was only associated with reduced liver weight 
and liver TGs in chow-fed animals (Figure 2.6D,E,F), while HFD-fed Hig2LKO 
animals displayed no alterations in liver TGs, liver weight, serum TGs, serum 
cholesterol, or serum NEFAs (Figure 2.6D,E,F, Table 2.1). One possible 
explanation for this is that other proteins may compensate for Hig2-deficiency in 
obesity-induced steatosis. For example, LD proteins such as Cidea and Fsp27 
are not expressed in healthy liver, but are highly induced with development of 
hepatic steatosis (200). It is likely that their expression promotes obesity-induced 
steatosis independent of Hig2 deletion. To test this hypothesis, Hig2LKO animals 
could be injected with a lentivirus containing shCidea and shFsp27 constructs to 
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silence Cidea and FSP27 gene expression in liver and then liver biochemistry 
could be analyzed.  Additionally, the mechanism by which Hig2 deficiency 
improves glucose tolerance in chow-fed animals and prevents obesity-associated 
glucose intolerance in HFD-fed animals is currently unknown. Chow-fed 
Hig2LKO animals displayed reduced liver lipids, a condition that has been 
correlated with improvements in insulin sensitivity (274), although this is not 
always the case (130). As HFD-fed Hig2LKO do not display reductions in liver 
lipids, the glucose tolerance improvement must be mediated by another means. 
For example, Hig2 deficiency could be altering the composition of liver lipids; the 
deficiency could increase the ratio of mono unsaturated FAs (MUFAs), the 
“benign FAs”, to harmful saturated FAs (SFAs) to improve metabolic health 
(315), although this is highly speculative and expression of inflammatory markers 
such as TNF, IL1, IL6, and F4/80 is unchanged (Figure 2.7A). Lipidomic 
analysis of fl/fl and Hig2LKO livers will have to be completed in the future to 
determine if Hig2 deficiency alters hepatic lipid composition; currently, the 
mechanism for the Hig2 deficiency-mediated improvement in glucose tolerance is 
still under investigation. 
 To probe the mechanism of the reduced liver lipids in Hig2LKO chow-fed 
animals, I assessed gene expression of a range of genes known to control lipid 
handling and found them to be unchanged in Hig2LKO livers as compared with 
controls (Figure 2.7B,C). I interpreted this result to mean that Hig2 deficiency 
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reduced lipid deposition independent of gene expression changes. The caveat 
with this conclusion is that this gene expression analysis is specifically targeted; 
thus, changes in genes I did not measure could be responsible for the reduction 
in liver lipids. To form a broader picture of gene expression changes in Hig2LKO 
animals, whole-genome microarray or RNA-seq analysis should be performed on 
control and Hig2LKO chow-fed livers. As I could not discern any expression 
differences in lipid handling genes in Hig2LKO livers, I hypothesized that Hig2 
deficiency may be altering lipid flux (enzyme activity, protein localization) 
independent of gene expression changes. To address this hypothesis, I 
performed tracer experiments with radioactive FAs, specifically [3H] oleic acid, in 
Hig2-deficient hepatocytes. I determined that Hig2-deficient hepatocytes 
contained less radioactive lipid (Figure 2.8A). Next, I determined that Hig2-
deficient hepatocytes had increased oxidation by measuring acid-soluble 
metabolites in the media of Hig2-deficient hepatocytes after overnight [3H] oleic 
acid loading (Figure 2.8B). As this method merely measures oxidation products, 
it would be valuable to confirm the results by directly measuring oxidation in 
Hig2-deficient hepatocytes. This could be done either by measuring the oxygen 
consumption rate (OCR) on a Seahorse flux analyzer during a mitochondrial 
stress test or by loading cells with [14C] oleic acid and quantifying the radioactive 
CO2 directly formed from respiration. I hypothesize that both of these assays 
would demonstrate that Hig2 deficiency directly increases oxidation. 
158 
 
 
 LD protein deficiencies often increase lipolysis; hence, I measured 
lipolysis via two different assays. As hepatocytes contain glycerol kinase, glycerol 
release cannot be used as readout of lipolysis (316). Thus, I demonstrated that 
Hig2-deficient hepatocytes have increased TG turnover (Figure 2.8C) and 
increased lipolysis (Figure 2.8D).  
The studies in this chapter support the hypothesis that Hig2 is a LD 
protein in hepatocytes that promotes both glucose intolerance and lipid 
deposition. Although the mechanism whereby Hig2 promotes lipid deposition is 
currently unclear, the lipid tracer experiments (Figure 2.8) suggest that Hig2 may 
inhibit lipolysis, -oxidation or both. Lipolytic inhibition is a well-characterized 
mechanism whereby LD proteins promote lipid deposition. For example, Perilipin 
1 potently inhibits adipocyte lipolysis (180) and Fsp27 interacts directly with 
ATGL to inhibit lipolysis (240). Additionally, although some LD proteins may 
directly interact with mitochondrial proteins, -oxidation can often be a 
consequence of increased lipid fuel being shunted to mitochondria, as in Fsp27 
and Cidea-deficient cells (203,220), although this is only speculation in the case 
of Hig2 deficiency. Furthermore, Hig2 has sequence similarity with G0S2, a 
known inhibitor of the lipase ATGL, in the region where it is known to bind with 
ATGL (Figure 2.9); thus, Hig2 could act similarly by physically inhibiting ATGL. 
This could be tested via a combination of biochemical and imaging experiments. 
Imaging of ATGL and Hig2 in hepatocytes could be done and colocalization 
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calculated. Additionally, co-immunoprecipitation experiments could be performed 
to determine if Hig2 and ATGL physically interact. Finally, ATGL imaging in Hig2-
deficient cells could be completed to determine if ATGL is mislocalized by Hig2 
deficiency.  There are still many unanswered questions about the role of Hig2 as 
a LD protein in hepatocytes, but the studies presented herein have laid the 
groundwork for future experiments by determining that Hig2 is a LD protein in 
hepatocytes that promotes lipid deposition likely by inhibiting lipolysis.                
A role for Hig2 as a LD protein in adipocytes 
 This section will discuss my interpretations, potential pitfalls, and future 
directions for the studies presented in Chapter III. In the studies detailed in 
chapter II, I found that Hig2 is indeed a LD protein in hepatocytes and that its 
expression promotes glucose intolerance and lipid deposition likely by inhibition 
of lipolysis. Through my expression profile analysis, I had determined that Hig2 
was also expressed in WAT and BAT (Figure 2.10B). Although I am currently 
unable to detect Hig2 protein in adipose tissue via western blot, new antibodies 
should be developed for protein level verification in future studies. Additionally, 
Hig2 was highly expressed in the adipocyte fraction of omental and 
subcutaneous adipose tissue from bariatric surgery patients (Figure 3.1B-D) and 
increased with obesity in murine eWAT (Figure 3.1A), suggesting that its 
expression may promote obesity-associated lipid deposition. Furthermore, Hig2 
expression significantly increased with adipogenic differentiation in the human 
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SGBS adipocyte cell line (Figure 3.1F). Interestingly, this was not the case for the 
murine 3T3-L1 adipocyte cell line (Figure 3.1E) or primary murine iWAT 
preadipocytes differentiated in culture (data not shown), suggesting a differential 
transcriptional regulation in mouse vs human. To fully confirm this, Hig2 
expression should be measured in isolated human preadipocytes differentiated in 
culture. Additionally, Hig2 protein levels should be measured upon adipogenic 
differentiation in mouse and human adipocytes, as these may differ entirely from 
Hig2 mRNA expression. These aforementioned results raise the question of how 
human and murine Hig2 transcripts differ in their regulation. One key difference 
between the human Hig2 gene and the mouse Hig2 gene is that the mouse Hig2 
gene is suggested to have two mRNA transcript variants; according to NCBI 
gene database, Hig2 transcript variant 1 is 288 nucleotides long and encodes a 
longer Hig2 isoform. Hig2 transcript variant 2 is 195 nucleotides long, contains an 
alternate 5' exon, and uses a downstream start codon, compared to variant 1; as 
such, it potentially codes a Hig2 protein with a shorter N-terminus. I have aligned 
these sequences with my Hig2 qPCR primers and have found that my primers 
detect both variants. In the future, non-overlapping primers should be designed 
and expression profiling should be done for each variant. Perhaps one variant is 
highly induced upon adipogenic differentiation, while the other is reduced. 
Although murine Hig2 transcript variation warrants further investigation, I did not 
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pursue it in this work because human Hig2 does not contain this transcript 
variation. 
       I strove to answer the same two questions in adipose tissue as I had 
in liver. One, is Hig2 a LD protein that promotes lipid deposition in adipocytes by 
inhibiting lipolysis and two, what is the role of adipocyte-specific Hig2 on whole 
body metabolism? 
To begin to answer these questions, I imaged endogenous Hig2 in mature 
SGBS adipocytes and found that Hig2 localized to Bodipy-positive LDs in these 
cells (Figure 3.2A,B). One particular caveat of this experiment is that I imaged 
with the antibody we made in conjunction with Rockland Immunochemicals and 
what I considered endogenous staining could merely be non-specific staining. 
Considering it is difficult to knockdown genes in human adipocytes and Hig2 is 
particularly difficult to knock down (data not shown), I confirmed that this staining 
was specific using a blocking peptide (data not shown). Additionally, I observed 
that undifferentiated SGBS cells had little to no Hig2 staining (data not shown), 
which aligned with Hig2 mRNA expression (Figure 3.1F), suggesting that the 
staining is indeed specific. I was able to confirm that ectopically expressed HA-
tagged Hig2 localizes to LDs in 3T3-L1 adipocytes (Figure 3.2C), but need better 
antibodies to determine the localization of endogenous Hig2 in murine cells. 
Interestingly, the LD localization pattern of Hig2 in culture adipocytes, particularly 
SGBS cells, is unique. Canonical LD proteins often form uniform rings around 
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LDs, much like GFP-Hig2 does in hepatocytes (Figure 2.1B), but in SGBS 
adipocytes, Hig2 does not localize to all LDs and coats certain LDs in a 
discontinuous pattern. This localization pattern warrants further investigation and 
suggests that Hig2 may be localized to certain contact sites on LDs, such as LD-
mitochondrial contact sites, LD-ER contact sites, or LD-LD contact sites. Further 
imaging and biochemical fractionation experiments will need to be done to 
answer this question.  
As I had determined that Hig2 was a LD protein in adipocytes, I proceeded 
to investigate whether its expression promoted lipid deposition by lipolytic 
inhibition and the role of adipocyte-specific Hig2 in whole body metabolism. To 
this end, I derived an adipocyte-specific Hig2-deficient mouse (Hig2AdKO) by 
using an adipocyte-specific adiponectin promoter-driven cre recombinase (Figure 
3.3A) and confirmed that Hig2AdKO animals had adipocyte-specific deletion 
(Figure 3.3B-D), although this should be further confirmed with immunoblots 
using newly developed antibodies in the future. I challenged Hig2AdKO animals 
with HFD, evaluated metabolic parameters (insulin tolerance test, glucose 
tolerance test, serum and liver biochemical analyses, histology, tissue weights) 
and determined that Hig2AdKO animals displayed improved glucose tolerance 
(Figure 3.4B), concomitant with a redistribution of ectopic lipids. Hig2AdKO 
animals had significantly reduced eWAT weight (Figure 3.6A), increased liver 
weight (Figure 3.6D), and, although there was no significant pad weight change, 
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BAT that was largely cleared of lipids (Figure 3.6G). These data suggest that, as 
in liver, adipocyte-specific Hig2 expression promotes both lipid deposition and 
obesity-associated glucose intolerance. Interestingly, the data also suggest inter-
organ communication, as the liver, an organ without Hig2 deletion, is affected. 
This will be discussed further later on in this chapter. 
As Hig2 is deleted in both WAT and BAT, I wanted to try and determine 
which tissue was responsible for the phenotype in the Hig2AdKO animals. As the 
BAT of Hig2AdKO animals was strikingly cleared of lipids, I focused on 
specifically targeting brown adipocytes. There are multiple ways to modulate BAT 
activity, such as temperature, BAT denervation and genetic deletion. I started by 
using temperature. Room temperature (23°C) presents a cold stress for mice, 
thereby promoting beta adrenergic stimulation, activating BAT, and increasing 
both food consumption and metabolism (60). By moving the Hig2AdKO mice to 
thermoneutrality (30°C), I removed this thermal stress, greatly reducing BAT 
activity and minimizing its contribution to whole body metabolism. When I moved 
HFD-fed Hig2AdKO animals to 30°C for four weeks and metabolically 
characterized them (insulin tolerance test, glucose tolerance test, serum and liver 
biochemical analyses, histology, tissue weights), I determined that all differences 
present in Hig2AdKO animals at 23°C were abrogated by thermoneutral housing. 
At 30°C, the Hig2AdKO animals had no improvement in obesity-induced glucose 
intolerance and were actually more glucose intolerant than fl/fl controls (Figure 
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3.7B). Furthermore, Hig2AdKO animals had no alterations in ectopic lipid 
deposition at 30°C; there were no differences in eWAT weight (Figure 3.8A), liver 
weight (Figure 3.8D), or, most strikingly, BAT lipid deposition (Figure 3.8G). 
These data suggest that the metabolic improvements in Hig2AdKO animals 
require functionally active BAT.  To further test this hypothesis, I proceeded to 
delete Hig2 specifically in brown adipocytes and compare the whole body 
metabolism to that of the Hig2AdKO mice. I derived a brown adipocyte-specific 
Hig2-deficient animal (Hig2BATKO) by using a brown adipocyte-specific Ucp1 
promoter-driven cre recombinase (Figure 3.11A) and confirmed that the deletion 
was specific (Figure 3.11B,C,D). I challenged these animals with HFD and 
evaluated their metabolic parameters (insulin tolerance test, glucose tolerance 
test, serum and liver biochemistry, histology, and organ weights) and found that 
Hig2BATKO animals displayed improved glucose tolerance (Figure 3.12B). This 
result suggested that Hig2 deletion in brown adipocytes may be wholly 
responsible for the glucose tolerance improvements in Hig2AdKO animals 
(Figure 3.4B). Surprisingly, Hig2BATKO animals did not demonstrate the 
alteration in organ-specific lipid deposition, as they did not differ from fl/fl controls 
in eWAT weight (Figure 3.13A), liver weight (Figure 3.13D), or BAT lipid 
deposition (Figure 3.13G). These results suggest that either white adipocyte-
specific Hig2 deletion is responsible for alterations in organ weights or that both 
white and brown adipocyte-specific Hig2 deletion are necessary to alter organ-
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specific lipid deposition. Future experiments genetically targeting Hig2 
specifically in white adipocytes are necessary to answer this question. 
The mechanism whereby brown adipocyte-specific Hig2 deficiency 
improves glucose tolerance is currently unknown, but recent experiments 
suggest that, in addition to its thermogenic properties, activated BAT may 
function as an endocrine organ and can secrete beneficial molecules that 
improve overall metabolic health (308-312). For instance, transplanting BAT into 
WAT of diabetic mice promoted adipogenesis and restored euglycemia 
potentially through increases in circulating insulin-like growth factor 1 (IGF1) 
(313). Thus, it would be of value to measure circulating IGF1 levels in both 
adipocyte-specific and brown adipocyte-specific Hig2-deficient animals. 
Furthermore, BAT secretes a pool of the active thyroid hormone triiodothyronine 
(T3) and although its contribution to systemic T3 is currently unknown, T3 has 
potent effects on metabolic rate, gluconeogenesis, and lipolysis (317). Fibroblast 
growth factor 21 (FGF21) has also recently been demonstrated to be synthesized 
in thermogenic BAT; it is a powerful promoter of glucose oxidation in a variety of 
tissues, such as liver and WAT (312). Thus, both T3 and FGF21 should also be 
measured in adipocyte-specific and brown adipocyte-specific Hig2-deficient 
animals. To take an unbiased approach in addition to measuring the candidates 
listed above, proteomic analysis should be performed on serum from fl/fl and 
Hig2BATKO animals. As all of these products are thought to be secreted by 
166 
 
 
stimulated BAT, it will also be useful to measure them in thermoneutrally housed 
Hig2AdKO animals.    
To elucidate the mechanism whereby Hig2 deficiency alters organ-specific 
lipid deposition in Hig2AdKO animals (Figure 3.6), I measured lipolysis and 
assessed gene and protein expression in adipose tissues of Hig2AdKO animals 
as compared with fl/fl controls. I hypothesized that Hig2 deficiency may increase 
eWAT lipolysis, thus reducing its weight. To test this hypothesis, I measured ex 
vivo glycerol release of basal and isoproterenol-stimulated eWAT explants 
(Figure 3.9A). I found no differences in basal or stimulated glycerol release 
(Figure 3.9A), or more systemic measures of lipolysis, such as serum NEFAs or 
serum glycerol (Table 3.1). Nonetheless, I assessed lipase and LD protein 
expression in eWAT from Hig2AdKO and fl/fl control mice. I was surprised to find 
that certain lipolysis-responsive genes such as ATGL and Fsp27 were increased 
in Hig2AdKO eWAT as compared with fl/fl controls (Figure 3.9B). Even more 
surprising was the highly significant increase in induction of phosphorylated HSL 
in the knockouts, independent of increases in other PKA substrates (Figure 
3.9E,F). These results suggest that Hig2 deficiency may specifically increase 
HSL phosphorylation independent of other lipolysis measures. I hypothesized 
that if this selective increase in lipolytic signaling, particularly pHSL, may be 
associated with the improvements in Hig2AdKO animals, that the changes would 
be abrogated in a condition where the improvements were abrogated: 
167 
 
 
thermoneutrality. To test this hypothesis, I measured all of the same parameters 
at 30°C and found that gene expression increases were abrogated (Figure 
3.10B) and that the induction of pHSL was also abrogated (Figure 3.10C,D). 
Taken together, these data suggest that although adipocyte-specific Hig2 
deficiency increases phosphorylated HSL, it may not alter lipid deposition by 
increasing lipolysis.  
These results pose two questions; one, how does Hig2 deficiency alter 
lipid deposition without altering canonical measures of lipolysis? Two, why is 
phosphorylated HSL induced at 23°C in Hig2-deficient animals independently of 
other PKA substrates? At this point, the mechanism whereby Hig2 alters lipid 
deposition in adipocytes is still unknown. Metabolic cage measurements of HFD-
fed Hig2 animals suggest that these changes are not due to increases in energy 
expenditure, physical activity or changes in food intake in Hig2AdKO animals 
(Figure 3.5). To fully explore the gene changes in Hig2-deficient animals that 
could be responsible for altering lipid deposition, microarray analyses should be 
completed with fl/fl and Hig2AdKO BAT and WAT. Because Hig2AdKO animals 
display changes in multiple tissue weights, including liver, a tissue in which Hig2 
is not deleted, I hypothesize that there might be inter-organ communication 
between these tissues. Adipose tissue secretes a variety of adipokines that are 
known to alter whole body insulin sensitivity and potentially lipid deposition (318). 
Adiponectin is one known beneficial adipokine that was unchanged between 
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genotypes (Table 3.1). Another beneficial adipokine that was not measured was 
the satiety factor Leptin. Conversely, detrimental adipokines, such as Adipsin, 
Resistin, and Lipocalin are known to promote insulin resistance and their 
secretion from Hig2-deficient adipose tissue could be reduced (319). It would be 
valuable to check the circulating levels of a variety of adipokines to determine if 
their altered levels are altering metabolism in the adipocyte-specific Hig2-
deficient animals. 
Additionally, it is currently unknown why Hig2 deficiency selectively 
increases pHSL independent of other PKA substrates. One explanation for this 
could be that, in addition to Perilipin 1, Hig2 provides a LD scaffold for HSL upon 
its activation. Perhaps HSL is highly activated, but partially mislocalized. I could 
test this hypothesis by isolating preadipocytes from Hig2AdKO animals, 
differentiating them in culture, and imaging for HSL to determine its localization. If 
Hig2 does act as a scaffold, I hypothesize that pHSL would be localized to the 
cytoplasm instead of the LD. Additional biochemical experiments, such as co-
immunoprecipitation and mutagenesis would also need to be done to confirm that 
Hig2 physically interacts with pHSL and that a certain Hig2 sequence is required 
for binding. The results of the ex vivo glycerol assays suggest that, unlike 
Perilipin 1, Hig2 is not fully required for stimulated lipolysis, as isoproterenol-
stimulated glycerol release was not blunted in Hig2-deficient cells.     
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Finally, the role of Hig2 as a hypoxia-inducible LD protein cannot be ruled 
out as a mechanism for the changes in the Hig2AdKO animal. Although 
controversial, it is thought that obese adipose tissue becomes more hypoxic due 
to enlarged adipocytes and increased tissue mass (140,320). I have shown that 
obesity increases Hig2 expression in murine eWAT (Figure 3.1A) and have not 
ruled out that this may be due to increased hypoxia.  Furthermore, adipocyte-
specific genetic deletion of upstream hypoxia-responsive factors Hif1 and Hif1 
also suggests that they are required for obesity-associated glucose intolerance 
and lipid deposition, as these animals displayed improved glucose tolerance and 
reduced fat mass and eWAT adipocyte size (321). This may be through a 
reduction in signal transducer and activator of transcription 3 (STAT3) activation 
by suppressor of cytokine signaling 3 (SOCS3), as hypoxia increases SOCS3 
and SOCS3 inhibits insulin signaling by binding to the insulin receptor and 
inhibiting autophosphorylation (321). Hig2 deficiency could function similarly and 
SOCS3 and STAT3 should be examined in Hig2-deficient adipose tissue, 
although other independent hypoxia-regulated pathways could also be involved. 
Although there are still many unanswered questions regarding the role of Hig2 as 
a LD protein in adipocytes, these studies have laid the groundwork for future 
experiments by establishing that Hig2 is a LD protein in human and mouse 
adipocytes and that adipocyte-specific Hig2 promotes lipid deposition.  
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The work in this thesis has established a role for Hig2 as a LD protein in 
liver and adipocytes. I have shown that Hig2 localizes to LDs in both tissues 
(Figure 2.1, 3.2) and that its deficiency reduces both obesity-associated glucose 
intolerance (Figure 2.6, 3.4, 3.12) and lipid deposition (Figure 2.4, 2.6, 3.6), likely 
through lipolytic inhibition in hepatocytes (Figure 2.8), but not through lipolytic 
inhibition in adipocytes (Figure 3.9, Table 3.1). As Hig2 is ubiquitously expressed 
(Figure 2.10), future experiments should be done to examine the role of Hig2 as 
a potential LD protein in other tissues. For instance, foam cells are critical for the 
development of atherosclerosis (322). Although I have not measured Hig2 
expression in isolated foam cells, Hig2 could be critical for lipid deposition in 
macrophages. Hig2 could also play a role in myocellular or cardiac lipid 
deposition. As hypoxia is dysregulated in cancer and human breast, prostate and 
colon cancer tumors with upregulated lipogenesis are associated with poor 
prognosis (169), Hig2 could also function as a LD protein that promotes lipid 
deposition in cancer cells. It will be of interest to determine whether the 
mechanism whereby Hig2 promotes lipid deposition is conserved in each tissue. 
Lipolysis readouts from Hig2-deficient liver (increased) and Hig2-deficient 
adipose tissue (unchanged) suggest that this may not be the case, but 
experiments pinpointing the exact mechanism still need to be done. Additionally, 
the role of human Hig2 needs to be further investigated and it would be of great 
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therapeutic value to detect, characterize, and validate Hig2 mutations in human 
patients.     
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